A population WB-PBPK model of colistin and its prodrug CMS in pigs: focus on the renal distribution and excretion.

Running head: WB-PBPK model for CMS and colistin in pigs

Alexis Viel^{1,2,3}, Jérôme Henri², Salim Bouchène⁴, Julian Laroche^{1,5}, Jean-Guy Rolland²,
Jacqueline Manceau², Michel Laurentie², William Couet^{1,3,5}, Nicolas Grégoire³

1. INSERM, Unit 1070, Poitiers, France

2. Anses, Laboratoire de Fougères, Fougères, France

3. UFR Médecine-Pharmacie, Poitiers, France

4. Certara, Paris, France

5. CHU de Poitiers, Poitiers, France

Corresponding author:

Nicolas Grégoire

Tel.: +33 5 49 36 64 36.

E-mail address: nicolas.gregoire@univ-poitiers.fr

Abstract

Purpose: The objective was the development of a whole-body physiologically-based pharmacokinetic (WB-PBPK) model for colistin, and its prodrug colistimethate sodium (CMS), in pigs to explore their tissue distribution, especially in kidneys.

Methods: Plasma and tissue concentrations of CMS and colistin were measured after systemic administrations of different dosing regimens of CMS in pigs. The WB-PBPK model was developed based on these data according to a non-linear mixed effect approach and using NONMEM software. A detailed sub-model was implemented for kidneys to handle the complex disposition of CMS and colistin within this organ.

Results: The WB-PBPK model well captured the kinetic profiles of CMS and colistin in plasma. In kidneys, an accumulation and slow elimination of colistin were observed and well described by the model. Kidneys seemed to have a major role in the elimination processes, through tubular secretion of CMS and intracellular degradation of colistin. Lastly, to illustrate the usefulness of the PBPK model, an estimation of the withdrawal periods after veterinary use of CMS in pigs was made.

Conclusion: The WB-PBPK model gives an insight into the renal distribution and elimination of CMS and colistin in pigs; it may be further developed to explore the colistin induced-nephrotoxicity in humans.

Keywords: colistin; CMS; kidneys; PBPK model; pigs;

44 **ABBREVIATIONS**

45 ADME: Absorption, distribution, metabolism, excretion

46 BLOQ: below the limit of quantification

47 BW: body weight

48 CBA: colistin base activity

49 CMS: colistimethate sodium

50 DV: observed value

51 fu: unbound fraction

52 GFR: glomerular filtration rate

53 GIT: gastro-intestinal tract

54 HPLC-MS/MS: high-performance liquid chromatography coupled with tandem mass spectrometry

55 IIV: interindividual variability

56 IPRED: individual prediction

57 IV: intravenous

58 IM: intramuscular

59 LOQ: limit of quantification

60 MRL: maximal residue limits

61 NLME: nonlinear mixed effects

62 OFV: objective function value

63 PBPK: physiologically-based pharmacokinetic

- 64 PK: pharmacokinetics
- 65 PRED: population prediction
- 66 RV: residual variability
- 67 SIR: sampling importance resampling
- 68 $t_{1/2}$: half-life
- 69 VPC: visual predictive checks
- 70 WB-PBPK: whole body physiologically-based pharmacokinetic
- 71
- 72 WP: withdrawal period

INTRODUCTION

Colistin is an old peptide antibiotic from the polymyxin family that is used in human and veterinary medicines. In food producing animals, colistin is widely used as colistin sulphate to treat bacterial digestive infections. The use of its pro-drug, the colistimethate sodium (CMS), is the most frequent in human medicine but CMS can also be found as animal treatment. In human, in many cases colistin has become the last resort antibiotic against multi-resistant bacteria (1). Colistin is the active moiety and is formed from CMS hydrolysis within the body (2). CMS is a mixture of methanesulfonated molecules, which are hydrolysed in colistin by loss of methanesulfonate groups (3). The structures of colistin and CMS are responsible for their complex absorption, distribution, metabolism, and excretion (ADME), which depend on poorly described biological mechanisms (see below). Because of the renewed interest for colistin, clarifying this complexity is nevertheless essential in order to improve dosing adjustments and to avoid toxic effects (4).

Colistin and CMS have a high molecular weight (1167 g/mol and 1632 g/mol, respectively) and are ionized (cationic and anionic, respectively) at physiological pH (5), implying a weak passage of cellular membranes and physiological barriers. Hence, their distributions are supposed to be mainly within the extracellular spaces (6). According to few studies in animals, colistin is also suspected to bind to tissues (7, 8). Concerning elimination mechanisms, CMS is partially excreted unchanged in urine, as seen in healthy humans and rats (2, 6). Conversely, colistin excretion in urine is very low due to a major tubular reabsorption after glomerular filtration (2), and colistin tends to accumulate in kidney tissue (9, 10). Specifically, colistin mainly accumulates within cells of the proximal tubules (11), where this extensive reabsorption takes place (12, 13). This is an active process for which carrier-mediated uptakes involving different renal transporters, like PEPT2 (14) or megalin (10), have been identified. Moreover, an accumulation of polymyxins in intracellular organelles (like mitochondria and endoplasmic reticulum) has been shown (12) which could be linked to cellular death-pathways (15)

and nephrotoxic effects (15, 16). Colistin metabolism has not been described, but considering its peptidic structure it probably involves hydrolysis mechanisms (1).

Thus, the disposition of CMS and colistin within kidneys is not fully understood but has great implication in clinical practice, due to the dose-limiting nephrotoxicity. Classical pharmacokinetic approaches could be used to describe plasma profiles of both compounds but are inefficient to handle tissue concentrations. Moreover, it is quite difficult to collect experimental data in humans, especially in tissues, for obvious ethical reasons. Physiologically-based pharmacokinetics (PBPK) modelling, based on animal experiments, is a pertinent approach for this task. In addition to their ability to describe tissue distributions, these models are useful to perform some extrapolations from animals to human (17). A previous whole-body PBPK (WB-PBPK) model has been developed for CMS and colistin from rat experiments (18). However, several assumptions were made, especially for the renal/urinary distribution of CMS and colistin, without experimental data in tissue to support them. One advantage of this PBPK model was the use of a non-linear mixed effect (NLME) modelling approach (19) in order to handle inter-individual variabilities. Here, we refined this WB-PBPK model using numerous experimental plasma, urinary and tissue data from pigs, with a special focus on kidney exposure to colistin. Pigs were chosen for their physiological proximity to human (20), facilitating future inter-specie extrapolations.

The description of colistin pharmacokinetics in whole body is also interesting in the veterinary field. Indeed, for food safety concern, maximal residue limits (MRL) for colistin have been defined in edible tissues originating from food producing animals (21), e.g. pigs. These MRLs ensure that consumers can eat products from animals treated with colistin, without risk for their health. Therefore, a period is necessary between the last administration and the production of foodstuffs in order that colistin concentrations decrease below the MRL. This time is regulatory defined as the withdrawal period (WP). Linear regression based-methods are traditionally used to estimate the WP (22). However, the development of population PBPK modelling for this purpose is on going, due to their ability to predict tissue concentrations (23).

The aim of this study was first the development of a population PBPK model in pigs for colistin and its prodrug, CMS, using a NMLE approach with a focus on the renal disposition of both compounds. As an application of this PBPK model, its predictive ability to describe plasma and tissue concentrations was then used for estimating withdrawal period of colistin in pigs, highlighting one of the advantages of this modelling approach.

MATERIALS AND METHODS

Chemicals

CMS (Colymicine 1 MIU; Sanofi Aventis, Paris, France) was used for all experiments. It was freshly reconstituted in 0.9% NaCl prior to each administration. To avoid any spontaneous hydrolysis of CMS into colistin, reconstituted CMS solutions were kept at +4°C and administered within the first hour after reconstitution.

Animals

Forty-six (46) crossbred female swine (Duroc × Landrace × Large white) were purchased from INRA (Le Rheu, France) with no history of polymyxin treatments. The animals were housed in collective pens and acclimatized for one week under standard farming conditions before the experiments. They were between 12 and 14 weeks old with a body weight (BW) ranging from 45 to 55 kg at the beginning of the experiments.

Then pigs were housed by groups of two for those receiving repeated intramuscular (IM) administrations. Pigs carrying a venous catheter were kept alone in metabolism cages for a maximum of 4 days.

Animal killing was performed with electronarcosis, that induced instantaneous insensibility, following by bleeding with aorta section.

All experiments were conducted in accordance with the local ethical comity and were registered under the references 2905-2015112717486085 and 6528-201608251410563.

In vivo experiments

- Catheter implantation

For pigs receiving at least one intravenous (IV) administration of CMS, central venous catheters were implanted. These animals were firstly sedated with an IM injection of ketamine at 20 mg/kg (Imalgène, Merial, Lyon, France) and xylazine at 2 mg/kg (Rompun, Bayer, Loos, France). Then, they were intubated and kept anesthetized by inhalation with isoflurane 2.5% (IsoFlo, Zoetis, Malakoff, France) during all the surgical procedure. An incision was performed on the neck under local anaesthesia with xylocaine (Xylovet, CEVA, Libourne, France). After dilaceration of superficial tissues and muscles, two catheters were implanted in the jugular vein, one for drug administration and one for blood sampling. After surgery, pigs rested 48 h alone in their box. Then, they were housed separately in metabolism cage in order to facilitate drug administration and blood/urine sampling.

- Sampling

Blood sampling: for pigs harbouring a venous catheter, 1.5 mL of blood was taken at each sample. Catheter was then flushed with heparinised saline solution. Pigs without catheter were restrained by an operator using a snout rope while a second one was sampling blood with a vacuum tube from the external jugular vein. Immediately after sampling, plasma was chilled on ice bath, then separated by centrifugation (3000 g) at 4°C and kept in polypropylene tubes at -80°C until assay.

Urine sampling: spontaneous urination was gathered only from animals kept in metabolism cage; volume of urine was measured and then a 20 mL-sample was kept in polypropylene tubes at -80°C until assay.

174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197

Tissue sampling: each organ (except muscles, fat and skin) was entirely collected after killing, weighted and its volume measured by water displacement. A sample was taken from the area of the left gluteal muscle (including skin) for skin and muscles analysis. A piece of abdominal fat was taken for the adipose analysis. Then, tissues were cut into small pieces, rinsed with saline solution, put into polypropylene tubes and kept at -80°C until assay. Tissues were chilled within the first 30-min following the euthanasia of pigs. The possible hydrolysis of CMS during that period, and its impact on the estimations of partition coefficients (see experiment n°3 below), were considered as negligible.

- Experimental setup for PBPK model calibration

Different dosing regimens (doses and route of administration) of CMS were administered for model calibration (a brief description is given in Table I). Some pigs were used for several experiments (n°1, 2 and 3, see below): in that case the potential residual concentrations from previous administrations were considered for modelling.

Experiment N°1/Plasma and kidney PK after a single IV administration (10 pigs): a 1-h constant IV infusion of CMS at 125,000 UI/kg of BW (corresponding to 3.75 mg/kg CBA or 10 mg/kg of CMS base (24)) was administered via the central catheter. Blood samples (n=12 per pig) were taken from 0.5 h to 32 h after the start of CMS administration. Urine samples were collected over two intervals (0-8h and 8-24h after CMS administration) for 6 pigs, and for the remaining 4 animals between 6 and 9 successive urine samples were collected depending on technician availability. Four pigs were sacrificed at 32 h and their kidneys were immediately removed and processed as described in sampling section.

Experiment N°2/Plasma PK after a single IM administration (6 pigs): CMS solution (125,000 UI/kg of BW) was administered as two injections of about 10 mL into gluteal muscle of each side. Blood samples (n=12 per pig) were taken from 0.25 h to 24 h after the injection.

Experiment N°3/Tissue partition coefficients (6 pigs): A dosing regimen was elaborated to achieve steady state of CMS and colistin in order to estimate the tissue to plasma partition coefficients (Kp): pigs were firstly infused during 1 h with a loading dose of CMS at 75,000 UI/kg; then a break of 1.5 h was done to get sufficient *in vivo* hydrolysis of CMS into colistin; finally, 50,000 UI/kg of CMS was administered as a 4 h-infusion. Blood samples were taken during the 4 h-infusion to assess steady-state in plasma; at the end of the infusion pigs were sacrificed and their blood, lungs, brain, heart, abdominal fat, skin, gluteal muscle, duodenum, liver and kidneys were immediately removed and processed as described in sampling section.

Experiment N°4/Plasma and kidney PK during and after repeated IM administrations (15 pigs): repeated CMS administrations were performed to study colistin renal accumulation. Pigs were randomly divided into 5 groups of 3 individuals. They received two IM injections of CMS per day at 25,000 UI/kg with a day-delay of 9 h (and 15 h during night). One group received 2 administrations (1 day) and were slaughtered 15 h after last injection; one group received 6 administrations (3 days) and were slaughtered 15 h after last injection; last 3 groups received 14 administrations (7 days) and were sequentially slaughtered at 15, 39 and 63 h after last injection. IM administrations were given on the neck and on top of gluteal muscles with a side alternation at each injection. Blood samples were taken during the treatment period in a sparse sampling way (between 1 and 3 per pig), each animal being sampled every 48 h at most. At sacrifice, blood and kidneys were collected and processed as described in sampling section.

- Experimental setup for model validation

Experiment N°5/Tissue and plasma PK after IM injections of CMS following the recommended veterinary dose (20 pigs): repeated CMS administrations were performed over 3 days with two IM injections per day at 25,000 UI/kg with a day-delay of 9 h (and 15 h during night). Then, pigs were sacrificed by groups of 4 at 1 h, 3 h, 5.5 h, 7.5 h, 15 h after last administration and their blood and fat, muscles, kidney, liver, skin (edible tissues) were collected as described above.

Determination of the unbound fraction (f_u) of CMS in plasma

The plasma f_u of colistin in pigs (40%) was obtained from the literature (25). As no value was retrieved for CMS in the literature, we determined f_{u_CMS} by ultrafiltration. Briefly, CMS was added to blank plasma from pig at a theoretical concentration of 5 µg/mL and 0.5 µg/mL, then ultra-filtrated through a cellulose-membrane (Centrifree, Merck, Alsace, France) by centrifugation (3000 g) at 37 °C during 30 min. A similar experiment was performed in buffer instead of plasma in order to take into account the loss due to CMS hydrolysis at 37 °C in plasma (3), and the potential non-specific binding of CMS to the lab material (5). All filtrates were kept at -20°C before assay (less than 1 week). All these experiments were realized in triplicates.

Analytical methods

Plasma and urinary CMS and colistin concentrations were assayed with a validated high performance liquid chromatography tandem mass spectrometry (HPLC-MS/MS) method using polymyxin B as internal standard, as described elsewhere (26). With this analytical method, CMS determination is achieved in an indirect way: a separate aliquot of each sample was pre-treated with sulphuric acid at 0.5M (for 1 h at room temperature) to hydrolyse CMS to colistin and the concentration of CMS was then determined by difference between the concentrations measured before and after the acid hydrolysis, accounting for the differences in molecular weights of CMS and colistin.

For tissues, this method was adapted. Briefly, standards and quality controls were prepared from blank tissues. A sample of 100 mg for each organ was taken and 980 µL of blank plasma was added

before homogenization with T-18 Ultra-Turrax homogenizer (KA®-Werke GmbH & Co. KG, Germany). Then 20 µL of a colistin solution (diluted in a 50/50 mix plasma/water) was added to obtain standard curves. After vortexing and centrifugation (4000 rpm for 10 min), supernatants were assayed as described for plasma (26). For samples, the same procedure was realized but 20 µL of a 50/50 mix plasma/water solution was added instead of 20 µL of colistin solution. Calibration range of colistin was from 0.020 µg/mL to 10 µg/mL in plasma and 0.2 to 100 µg/g in tissues; the concentrations of quality controls were at 0.16, 0.63 and 3.80 µg/mL in plasma and 0.5, 5 and 75 µg/g in tissues; the limit of quantification were 0.02 µg/mL for colistin in plasma; 0.2 µg/g for colistin in all tissues. For CMS, the LOQ was 0.15 µg/mL in plasma and 1 µg/g in tissues.

For the assay in kidney, the intracellular localization of colistin made imprecise the discrimination between colistin and CMS concentrations. Indeed, the lysis of cells occurred both during the crushing phase and the acidic phase used for CMS determination. Therefore, the concentrations measured in kidneys corresponded to the sum of CMS and colistin, expressed as colistin.

Development of the PBPK model

- Model structure

The PBPK model was based on a previous published model developed from rats, using plasma and various tissue concentrations (18). It is composed of 9 compartments corresponding to the main body organs (lungs, heart, liver, fat, skin, gastro-intestinal tract, brain, muscles, and kidneys), two blood compartments (arterial and venous) and one excretion compartment (urine) (Fig. 1A). Remaining body was lumped into a compartment named “rest of body”. Volumes of compartments and blood flows were fixed to physiological values reported in the literature (25, 27-42). These values depended on individual bodyweights and cardiac output (which also depends on bodyweight), respectively (Table II). The cardiac output was corrected by the haematocrit to get the total plasma flow. Because molecular weights of CMS and colistin are small with respect to passage across endothelial walls, it

was expected that distribution within extracellular fluid was rapid (6) and a perfusion limited model was assumed for all organs except kidneys in which active intra-cellular transport occurs (see below).

Drug distribution in each tissue compartment (except kidney and bladder) was upon the dependency of Kps. CMS and colistin Kps were determined at the end of the perfusion established to reach the steady state for both drugs (experiment n°3) as follows (Eq. 1):

$$Kp = \frac{C_{tis_ss}}{C_{plas_ss}} \quad (\text{Eq. 1})$$

where Kp is the partition coefficient of the tissue, C_{tis_ss} is the concentration measured at steady-state in the overall tissue, i.e. containing both extracellular and intracellular spaces; C_{plas_ss} is the plasma concentration of CMS or colistin at steady-state.

The hydrolysis of CMS into colistin was assumed to take place in every compartment (including plasma), with a common hydrolysis constant (K_{hyd_CMS}) (Fig. 1B). This assumption was supported by a previous experiment in rats, showing no significant differences of the hydrolysis rates between plasma and various tissue homogenates (18). This constant was estimated during model calibration. Thus, for each tissue an intrinsic hydrolysis clearance (CL_{hyd_CMS}) was expressed as follows (Eq. 2):

$$CL_{hyd_CMS} = V_{tissue} \cdot K_{hyd_CMS} \quad (\text{Eq. 2})$$

Where V_{tissue} is the volume of the corresponding tissue.

For colistin, the elimination occurs via mechanisms not yet described. Similar to CMS, an elimination process was defined based on a constant (K_{deg_COLI}) common to all the organs (Fig. 1B) and estimated during model calibration. The intrinsic degradation clearance (CL_{deg_COLI}) was defined as (Eq. 3):

$$CL_{deg_COLI} = V_{tissue} \cdot K_{deg_COLI} \quad (\text{Eq. 3})$$

Where V_{tissue} is the volume of the corresponding tissue.

Kidneys were divided into sub-compartments (Fig. 2) due to the particular distribution/elimination pathways of polymyxins within this organ. Renal vascular, extra-vascular and tubular intracellular spaces as well as luminal proximal tubular compartments were defined. CMS was eliminated in kidneys either by urine excretion or by hydrolysis into colistin. The latter one was assumed to take place in every sub-compartments of the kidney (according to a constant rate K_{hyd_CMS}). Concerning the urine excretion of unchanged CMS, it was due either to glomerular filtration or potentially to secretion of CMS from the extra-vascular space to the tubular lumen (through tubular cells), as outlined for rats in a previous study (2). Therefore, a glomerular filtration clearance (CL_{GFR_CMS}) was included in the structure of the base model, originating from kidney vascular space compartment and going into the proximal tubules one (43). CL_{GFR_CMS} was calculated as the product of the glomerular filtration rate (GFR) and the fu_{CMS} in plasma (experimentally determined). The potential secretion of CMS was tested during model development.

Within kidney, colistin was also eliminated either by urine excretion or by metabolism (degradation). The urinary excretion corresponded to the colistin filtrated by the glomeruli (expressed by CL_{GFR_COLI}) that was neither metabolized nor reabsorbed within the tubules. Indeed, colistin undergoes major tubular reabsorption: it was observed that more than 90% of excreted colistin was reabsorbed in rats (9). Colistin is then mainly located in proximal tubular cells as shown with *in vitro* studies with polymyxins (11-13). Therefore, a reabsorption clearance of colistin (CL_{reabs_COLI}) was estimated in the model, originating from the tubular lumen into the intracellular sub-compartment. Colistin renal metabolism was assumed to take place in every sub-compartment (at constant rate corresponding to K_{deg_COLI}). Due to the lack of data and the kidney physiology that is close between human and pig (20), the flow in the proximal tubule (Q_{tub}) was fixed to the human value, i.e. about 67% of GFR (44). Bladder compartment was used as a transitory compartment receiving urine from tubular lumen and evacuating it, with an exit flow (Q_{uri}) determined in pigs kept in metabolism cage. This compartment was not considered as a vascularized tissue (no distribution).

For IM administrations, a compartment of depot was added (45). Two absorption rate constants originating from this depot compartment to the venous one were estimated, one for CMS (K_{IM_CMS}) and one for colistin (K_{IM_COLI}). Intrinsic hydrolysis of CMS and elimination of colistin were supposed to occur in this compartment such as in all other compartments (Fig. 1C).

The control file describing the PBPK model is presented in the supplementary files.

- Model calibration and modelling method

A NLME modelling approach was used for the estimation of unknown parameters, inter-individual variabilities (IIV) and residual variabilities (RV) (19). Model structure was modified if needed and model selection was based on the physiological plausibility (as described above) and a parsimonious approach. A decrease of the objective function value (OFV) of more than 3.84, corresponding to a 5% significance level, was considered as a significant improvement in model fit. The sampling importance resampling (SIR) method (46) was used to obtain the 95% confidence intervals (IC 95%) of the parameter estimates (5 iterations with 1000, 1000, 1000, 2000, 2000 samples and 200, 400, 500, 1000, 1000 resamples for each).

For IIV, a log-normal distribution of parameters was assumed. IIV was firstly estimated for each parameter separately and retained only if a significant decrease in OFV was observed without adding uncertainties in the estimation of fixed effects (forward selection process). In a second step, all IIV parameters for which the p-value was <0.05 in the univariate analysis were included in the model, and a stepwise backward selection was then performed, with a threshold of p-value of <0.05. .

For RV, additive and proportional error structure models were tested. Furthermore, for CMS and colistin concentrations determined in the same sample (see details of the analytical method), the L2 data item method was used in order to estimate potential correlation between their RV (47). The M3 method was used to handle data below the LOQ (BLOQ) (48).

The calibration step was performed with all experimental data described in section “Experimental setup for model calibration” and summarized in Table I. Concentrations were log-transformed before modelling. For urine data, CMS and colistin could not be discriminated due to the spontaneous hydrolysis of CMS into colistin after excretion (2, 6). Thus, all observed concentrations were converted as CMS quantities (thanks to molecular ratio and measured urine volume) and pooled. Accordingly, urinary CMS and colistin model predictions were also pooled. Predictions in kidney corresponded to the amount of colistin and CMS in the different kidney sub-compartments (vascular, extra-vascular, intracellular and tubular lumen) divided by the sum of their respective volumes. Moreover, colistin and CMS concentrations in kidney were pooled for the analysis (*cf.* analytical methods).

The determination of CMS and colistin half-lives in plasma and kidneys was done by graphical identification of the different phases of decrease for predicted concentrations in log-scale, and then by calculating the time required for the typical concentrations to decrease by 50% in each phase. Total clearances of each compound were calculated as the dose of CMS, or as the total formed quantity of colistin, divided by the area under the curve of the plasma CMS, or colistin concentration, respectively. The renal clearances (CL_R) in this study accounted for the removal of compounds in kidney by different routes, *i.e.* secretion/excretion processes and hydrolysis of CMS or degradation of colistin. Thus, they were defined as the product of renal extraction ratio by the renal flow (Q_{kid}):

$$CL_R = \frac{(C_{art} - C_{kid_VA})}{C_{art}} \cdot Q_{kid} \text{ (Eq. 4)}$$

With C_{art} : arterial concentration of CMS or colistin; C_{kid_VA} : concentrations of CMS or colistin in renal vascular compartment.

- Model evaluation

The performances of the PBPK model were tested in a 2-step approach. An internal validation was firstly done based on graphical and statistical criteria. Goodness-of-fit was assessed by plotting

observed (DV) versus individual predictions (IPRED) and population predictions (PRED). Then Visual Predictive Checks (VPC) were generated, stratified by experimental designs and organs, with 1000 simulated replicates from the calibration dataset (Experiments n°1 to n°4, see Table I). The 5th and 95th percentile of the model predictions were plotted to check if 90% of the experimental data were included within this interval.

Then, an external validation was done with the independent dataset that was not used for calibration (Experiment n°5). This experiment followed the recommended veterinarian CMS doses. All parameters estimated during model calibration (fixed and random effects) were fixed. No RV was estimated for concentrations in tissues (except kidneys) during calibration because these tissue data were only used to determine the CMS and colistin Kps. Therefore, a common RV value between those estimated in plasma and kidney was chosen for the predictions of colistin concentrations in all other tissues. Concentrations of CMS and colistin within each organ were simulated with the final model and the predictive ability of the PBPK model was assessed by visualizing the distribution of the validation dataset within the 90% prediction intervals (10% of the data expected to be outside the interval). Only compartments involved in withdrawal period calculations (fat, skin, muscles, liver and kidney) and plasma were analysed.

A local sensitivity analysis was performed on the estimated structural parameters to assess their influence (associated to potential uncertainties) on model predictions. This analysis was performed only for kidney predictions, which was the main tissue of interest. The sensitivity analysis consisted in a $\pm 10\%$ perturbation of each parameter estimate, all other parameters estimate being unchanged. The output considered for sensitivity was the time when the median model prediction for concentration in kidney fell below its MRL (0.20 $\mu\text{g/g}$).

- Model application: Withdrawal period estimation

To estimate withdrawal period, we generated a 98 % prediction interval (*i.e.* 99% unilateral) (49) from 1000 simulations of the individual predicted profiles (without RV) of virtual pigs of 50 kg receiving the dosing scheme of CMS used in veterinary medicine. Then, the same approach was done with a virtual pig of 100 kg (which is close to the real slaughter weight). These simulations were performed with all structural parameters and their IIV (if present) estimated with the final model. Times for which the upper prediction limit fell below the MRL for each tissue intended for human consumption were determined. Then, the highest time from all of them was chosen as the final withdrawal period.

Software

The modelling was performed using NONMEM 7.4 (ICON Development Solutions, Ellicott City, Maryland, USA) with the first order conditional estimation method including eta-epsilon interaction (FOCE-I) and ADVAN 14. Perl speaks NONMEM (50) and Piraña (51) were used in order to facilitate the modelling work. All graphs were done using R software (version 3.4.1, www.R-project.org).

RESULTS

- Unbound fraction of CMS in plasma

We experimentally determined the f_{u_CMS} by ultra-filtration at 37°C (Table III). About 28 % of CMS was lost in buffer solution due to the CMS hydrolysis and to the non-specific binding to the tube. The measurement of colistin concentrations in the buffer samples at 37 °C indicated that less than 6% of CMS was hydrolysed into colistin after 30 min (data not shown). Moreover, we had previously estimated in human and rat plasma samples spiked with CMS and kept for 30 min at 37°C, that about 8% of CMS was converted into colistin (in-house data). Therefore, the hydrolysis of CMS in plasma and buffer were quite low over the period of this experiment (30 min) and could be considered as negligible. Overall, by neglecting the degradation of CMS into colistin and assuming that the non-

specific binding was similar during the ultrafiltration experiments in plasma and buffer, the average $f u_{CMS}$ was estimated to be $37 \pm 3 \%$ in pigs.

- Model structure and calibration

The structure of the base model was developed in order to fit the experimental data. Colistin Kps were calculated as the ratios of concentrations measured at steady-state in tissue and plasma. However, for muscles, 3 concentrations over 6 were below the LOQ and were fixed at LOQ/2 for calculations of Kps. Results for Kps of colistin are reported in Table II. Concerning Kps of CMS, about 80% of tissue concentrations (except kidney) were under the LOQ ($1 \mu\text{g/g}$ of tissue) at steady-state. Therefore, these Kps could not be measured experimentally and were estimated by the model (M3 method for data below the LOQ). However, estimation of one specific Kp for each organ was impossible and a Kp of CMS common for all tissues (Kp_{mix_CMS}) as well as a common RV value for CMS concentrations in tissues were estimated (except for kidneys).

One additional compartment was added to each vascular compartment (arteries and veins) in order to fully describe the plasma colistin kinetic profile. These two compartments, referred as "deep compartments", were volume-less and with two different estimated transfer constants (K_{DEEP_COLI} and $K_{DEEP_OUT_COLI}$) (Fig. 1D).

Structural modifications were needed for the kidney sub-model (permeability-limited model). Due to the protein binding of CMS, a secretion clearance of CMS (CL_{sec_CMS}) from the extra-vascular compartment towards the tubular lumen through the intracellular compartment was added to explain the urinary excretion of CMS (Fig. 2). A rate of degradation of colistin (K_{deg_COLI}) in kidneys different from that in other organs was estimated but did not improve significantly the fitting. Non-linear mechanisms for renal elimination of colistin were also tested, without significant improvement of the fitting. An intracellular binding compartment (volume less) significantly improved the fitting (OFV decrease of 20), with two different estimated "in and out" transfer constants (K_{ON_COLI} and

K_{OFF_COLI}). Because CMS and colistin could not be distinguished in urine, the fraction of colistin reabsorbed in proximal tubules could not be accurately estimated. Therefore, the proportion of colistin reabsorbed (driven by CL_{reabs_COLI}) was estimated from data in human healthy volunteers (6) and fixed at 97.5%.

The parameter estimates of the PBPK model after model calibration are reported in Table IV. For each structural parameter, CI 95 % were satisfying (the wider interval being for the colistin absorption constant from IM depot, K_{IM_COLI}) highlighting the good precisions of the estimates. Overall, uncertainty for CMS parameters was lower than for colistin ones. Proportional residual errors were chosen as the best error models and the highest estimated RV was for kidney concentrations (57%). Two inter-individual variabilities, one associated to K_{deg_COLI} (26.6%) and the other to CL_{SEC_CMS} (43.5%), were estimated.

- Model evaluation

Model diagnostics showed acceptable goodness-of-fit plot for the final model (supplementary material, Fig. S1). The VPCs generated for the internal validation showed a good agreement between model median predictions and CMS and colistin concentrations measured in plasma, either after one IV of CMS (experiment n°1, Fig. 3A), one IM of CMS (experiment n°2, Fig. 3B) or after the dosing regimen implemented to achieve steady-state (experiment n°3, Fig. 4A). Median predictions of plasma concentrations were also reasonably well described after repeated IM administrations (experiment n°4, Fig 4B), even if the median predictions were slightly below the measured peak of plasma concentrations for both compounds. However, distribution and elimination phases were well fitted. The wide prediction intervals, though, highlighted that variability could be overestimated. Overall, data BLOQ were well predicted by the model as shown on Fig 3A and 3B. For the repeated IM injections, collected data were sparse so the fractions of data BLOQ were not presented due to

graphical reasons. However, the only discrepancy was at 9 h just before the second IM injection because all observed colistin data were BLOQ in contrast to the model prediction (Fig 4B).

Concerning kidney sub-model, cumulative urinary amounts after one IV administration of CMS were well predicted by the model (Fig. 5). For concentrations in kidney, the typical prediction captured well the renal accumulation (Fig. 6C), but there was a high variability between the different experiments, with some under-predictions (Fig. 6B) or over-predictions (Fig. 6A and late points of Fig. 6C). This variability was taken into account by the model thanks to the high estimated IIV and RV. However, the large 90% PI suggest that variability could be overestimated in kidneys.

To assess the PBPK model predictive ability, an external validation was performed with an independent dataset that was not used during model calibration. Median plasma concentrations of both compounds were quite well fitted by the model typical predictions (Fig. 7). In kidneys, the elimination phase was in good match with observed data (Fig. 8) but the typical prediction under-estimated the maximal concentrations. For other tissue concentrations, most of the observed data were below the LOQ for CMS and colistin (Supplementary files, Fig. S2 and S3) and this was well predicted by the model. However, typical concentrations of CMS in muscles and of colistin in skin were slightly under-predicted. Overall, these results gave good confidence in the PBPK model predictive ability, even if there was a slight overestimation of the total variability.

- CMS and colistin pharmacokinetics in plasma and tissue

After IV and IM injections of CMS, plasma concentrations of CMS declined quickly and were under the LOQ 8 h post-administration (Fig 3A and 3B). By contrast, colistin plasma concentrations declined slower and were still quantifiable more than 24 h after CMS administration. The estimated half-life ($t_{1/2}$) of CMS was 1.2 h. For colistin, an initial (lasting from 0 to 10 h after dosing) half-life of distribution of 1.8 h was calculated, followed by a terminal half-live of 10.5 h. This terminal $t_{1/2}$ for colistin was

described in the model thanks to the additional deep compartments. The maximal concentrations of colistin were predicted to occur 1 h after the end of the IV infusion, or 2 h after IM injection. As shown by the median prediction in figure 4A, the plasma steady-state of CMS and colistin was achieved at the end of experiment n°3 for Kp determination, thanks to the use of a loading dose of CMS. Concerning drug elimination, total CMS clearance was estimated to 11.6 L/h for a virtual pig of 50 kg, whose 7.9 L/h was associated to renal clearance, which included the glomerular filtration, the tubular secretion and the CMS hydrolysis within kidneys. For colistin, the total clearance was found to be at 7.4 L/h whereas the renal clearance, which was mostly due to intracellular metabolism, accounted for 1.5 L/h (see below).

For tissues other than kidneys, all colistin Kp values were less than one (Table II) as well as the common estimated Kp for CMS (Table IV). In kidneys, the CMS concentrations were predicted to decrease quickly after an administration of CMS (Supplementary material, Fig. S4). Therefore, we can consider that at late time points after administration there was only colistin remaining in kidneys. Residual renal concentrations were still high 31 h after the single IV injection ($7.0 \pm 3.4 \mu\text{g/g}$, Fig. 6A) and 63 h after the last IM injection ($5.6 \pm 1.9 \mu\text{g/g}$, Fig. 6C); the terminal $t_{1/2}$ of colistin in kidneys was estimated to be about 38 h. After twice daily IM administrations of CMS 25,000 UI/kg, colistin concentrations in kidney were $7.0 \pm 1.3 \mu\text{g/g}$ after 1 day (2 doses), $14.7 \pm 9.9 \mu\text{g/g}$ after 3 days (6 doses) and $24.6 \pm 5.9 \mu\text{g/g}$ after 7 days (14 doses) (experiment n°4, Fig. 6C). The model predicts that steady-state in kidney should be almost reached after 5 days of treatment.

The relative disposition of CMS and colistin within the kidneys as predicted by the PBPK model is presented on Figure 9. Typically, 68% of the initial dose is predicted to be excreted in urine as a mix of CMS and colistin, with 56% due to the net tubular secretion of CMS and only 12% due to the glomerular filtration of CMS. In urine, CMS accounted for more than 99% of the total quantities. Among the fraction of the CMS dose converted into colistin (32%), only 2% were converted into the kidney. Colistin extraction ratio in kidney would be 18%, with glomerular filtration of the unbound fraction in plasma,

almost complete reabsorption (0.2% of formed colistin excreted in urine) and intracellular degradation in proximal tubules. Overall, kidneys would account for 20% of total colistin clearance. For the other compartments, the evolution of the mass balance of CMS and colistin after one IV of CMS are represented in the supplementary materials (Fig. S5).

- Model application: withdrawal period estimation

The withdrawal period was calculated from depletion in kidneys because colistin concentrations within this organ remained the longest above the LMR. The simulation of the PBPK model gave a WP of 23 days for a virtual pig of 50 kg (Fig. 10) and 25 days for a virtual pig of 100 kg (Supplementary material, Fig. S6). The sensitivity analysis revealed that K_{ON_COLI} , K_{OFF_COLI} and K_{deg_COLI} were the 3 parameters that particularly influenced the output, *i.e.* the time when the median model prediction of the renal concentration fell below the MRL. The most influential parameter was K_{OFF_COLI} , because 10 % variation of its value caused 8 % to 9 % variation of the output (Table V).

DISCUSSION

A whole body PBPK model was developed for colistin and its pro-drug, CMS, with a nonlinear mixed effect modelling approach. This model could reasonably well predict the median CMS and colistin concentrations in plasma (Fig. 7) and tissues, especially for kidneys (Fig. 8). For pigs, the PK of CMS in plasma was monophasic, with a $t_{1/2}$ of 1.2 h, whereas the PK of colistin was biphasic, with a distribution $t_{1/2}$ of 1.8 h and a terminal $t_{1/2}$ of 10.5 h (Fig 3A and 3B). These half-lives in pigs were in good agreement with those in healthy volunteers (6) except that a monophasic elimination of colistin was described. However, this biphasic profile was also observed in sheep, another large-animal model (52). As colistin is known to non-specifically bind to biological and non-biological matrix (7, 53, 54), deep compartments linked to vascular ones were implemented in the PBPK model to fit the plasma

concentrations of colistin at late time points. These compartments may reflect either a permeability-limited distribution of colistin in some organs, *e.g.* due to a weak intracellular penetration, or a high affinity binding to some extracellular component (*e.g.* red blood cells (55)), thus resulting in a slow release of colistin towards plasma. However, evidences of these mechanisms should be sought in experimental studies.

Concerning distribution, plasma unbound fraction of CMS was determined for the first time in pigs, thanks to an ultra-filtration method and by taking care of CMS degradation and potential adsorption to laboratory material. This value (37%) was close to that of colistin (40%) found in literature for pigs (25), highlighting a non-negligible protein binding. Colistin is known to bind to α -1-acid glycoprotein (at least for human) due to its cationic properties (56) but the mechanisms of CMS protein binding have not been investigated yet. Regarding tissue distribution, all K_p values (experimental ones for colistin and estimated ones for CMS) were lower than 1. This result reflected a poor distribution into tissues that could be in accordance with an extracellular distribution of CMS and colistin within organs. Our values were in good agreement with the experimental K_p s determined in rats for colistin (18), suggesting that these values could be used for inter-species extrapolations.

Concerning the elimination, CMS total clearance was higher (0.23 L/h/kg) than the colistin one (0.15 L/h/kg) for a standard pig weighting 50 kg. These results compare favourably with previous results in pigs (57). By contrast, these clearances are greater than those reported in healthy volunteers for CMS and colistin (0.12 L/h/kg and 0.040 L/h/kg for a man weighting 73 kg, respectively) (6), which is in contradiction with the classical allometry scaling laws based on weight (58). Therefore, extrapolation of clearances between the two species may be challenging.

To our knowledge, this is the first time that an accumulation of colistin in kidneys was quantified over time after repeated CMS administrations. Indeed, after a twice-daily IM administration of CMS (50,000 UI/kg/day) for 7 days, colistin concentrations in kidney were more than 3-fold higher than after the first administration (Fig. 6C). This was related to the long $t_{1/2}$ of colistin estimated in this

organ (~38 h). A previous study in rats already attested that the concentrations of colistin were high in kidney after 7 days of treatment (65.7 fold higher than in plasma), but the renal accumulation was not investigated over time (59).

To go further into the underlying mechanisms of the renal disposition of CMS and colistin, we divided the kidney into physiological sub-compartments (Fig. 2) (43). The unbound fraction of CMS in plasma, estimated herein, implied a tubular secretion of CMS because glomerular filtration was insufficient to explain the amounts measured in urine (Fig. 2). According to our model, this tubular secretion was the major elimination pathway for CMS in kidney, 4 to 5-fold higher than glomerular filtration (Fig. 9). This net tubular secretion of CMS into urine was already supported by studies in rats (2) and suggested in humans (60), but as the unbound fraction of CMS in plasma was unknown, it remained hypothetical. The median proportion of the initial dose of CMS excreted in urine was predicted to be 68 %, in accordance with the 60 to 70 % of CMS dose recovered in urine in rats and humans (2, 6).

Regarding colistin pharmacokinetics in kidneys, the tubular reabsorption is known to be carrier-mediated thanks to PEPT2 and megalin (10, 14). In our model, the clearance of reabsorption from the tubular lumen (CL_{reabs_COLI}) was fixed to a physiological value estimated from data in man (6), due to an identifiability problem. This reabsorption explained the colistin accumulation within tubular cells and the very small amount of colistin excreted in urine. Colistin might also undergo a tubular secretion, as for CMS, but because of the predominant reabsorption, this was not identifiable by our model.

Several hypotheses were considered in the model to describe the colistin accumulation in kidneys and its slow elimination in this organ. For instance, we tried to estimate a different colistin intrinsic constant of elimination (K_{deg_COLI}) in kidney, or to estimate a release of colistin from the kidneys towards the systemic circulation. However, these hypotheses did not improve the fitting or parameters were not identifiable. Moreover, the latter assumption, besides the modelling results, was also in contradiction with the results of previous studies showing *in vivo* that when the reabsorption

of colistin or polymyxin B in renal tubules was inhibited, the renal exposures was reduced considerably but the kinetic profiles in plasma remained unaltered (10, 61). The fact that total clearance of polymyxin remained unchanged, whether the reabsorption was inhibited or not, suggested that polymyxin was eliminated within the kidney, either excreted in urine or metabolized, but did not go back to the systemic circulation. Finally, the use of a renal intracellular “binding” compartment, with a slow release, was the best choice for the goodness-of-fit and for physiological reasons. Indeed, the observed colocalization with cell organelles (12) and the known non-specific binding properties of polymyxins to cellular membranes (1) could support this assumption. Sensitivity analysis suggested that these intracellular binding parameters were the parameters that most influenced the kidney exposure to colistin (Table V). This kind of intracellular binding has already been presented in another PBPK model developed and validated for doxorubicin (belonging to an antitumor antibiotic family) (30). Furthermore, due to this intracellular accumulation, about 20 % of the total formed colistin quantities were predicted to be metabolized within the kidneys, highlighting a major role of kidneys in colistin elimination. Further *in vitro* studies should be performed to investigate this intracellular binding and the intra-renal elimination.

These new renal data, about CMS tubular secretion and colistin accumulation over time, may be useful to explore the nephrotoxicity associated to the use of CMS and colistin. Indeed, in a recent meta-analysis, nephrotoxicity ranged from 24% to 74% in CMS-treated patients but most of the events were reversible (62). The duration therapy and the daily dose are risk factors of renal toxicity (1). In our study, the renal steady-state was quasi-achieved after 5 days of treatment (>120 h) and high renal concentrations were reached (>20 µg/g) (Fig. 6C). However, no clinical sign of renal insufficiency was observed in our animals and the creatinine concentrations in plasma stayed within the normal range over the whole treatment period (data not shown). Nevertheless, measurement of other biomarkers (like urinary creatinine or plasma cystatin C) might have been better to detect early signs of nephrotoxicity (63), in addition to histological analysis. According to modelling results, the intra-renal

conversion of CMS into colistin was very minor compared to the colistin that was reabsorbed and accumulated inside tubular cells. The accumulation of polymyxin inside proximal tubular cells is supposed to be responsible for the nephrotoxic effects involving apoptosis and oxidative stress (15, 16). However, the model slightly underestimated peak concentrations in kidney (Fig. 8), which may be of importance for nephrotoxic predictions. Of note, a high amount of CMS (56% of initial dose) transited inside tubular cell. This is important as CMS (and its numerous partially methanesulfonated derivatives) is invoked as a potential contributor to the observed nephrotoxic effects (60). Nevertheless, this model could be refined when new data will be available.

As a model application, we chose to estimate the withdrawal period (WP) after IM injections of CMS in pigs following the veterinarian recommended doses. WP is defined as the time after last administration for which 99 % of animals have residual edible tissue concentrations below the MRL, in Europe. Kidney was the tissue of interest because of the accumulation and of the slow colistin depletion (Fig. 8), compared to all other edible tissues (Supplementary files, Fig. S2 and S3). Simulations from the PBPK model gave an estimated WP of 23 days for a 50-kg pig. Since our last experimental concentration was measured 3 days after last administration, further experimental data around the estimated WP would have been preferable to confirm it. Overall, the model prediction seemed reasonable as our estimated WP (23 days) was close to the official one given in the summary of product characteristics of the veterinary medicinal product (21 days). The renal accumulation observed in our repeated CMS injections experiment highlighted that an extra label use of CMS would probably need longer WP. No data of such use for colistin are currently recorded but the use of PBPK models in these extra label situations has already proved its interest (64). Furthermore, this PBPK model was developed with colistin and its prodrug CMS but it could be easily adapted to pigs injected directly with colistin, as possibly done in veterinary medicine (65).

To our knowledge, this is the first study using a NLME approach for a PBPK model related to withdrawal period calculation. The process of PBPK models development for food safety is well

established as explained in a recent review of veterinary pharmacology (23). This method allows to predicting the time course of drug concentrations in any tissue of interest. Different doses and route of administrations can be used to develop a PBPK model as we did, enhancing its robustness of prediction (23). The classical statistical methodology for WP estimation uses inferences on a limited number of healthy animals whereas the real-life target is diseased animals. We also used healthy animals but the PBPK model can easily handle patho-physiological changes of parameters, like for a diseased animal, to see the effect on tissue drug concentrations. In addition, the use of NLME modelling brings many advantages. Noticeably, it gives estimation of population variabilities like inter-individual variability, which is discriminated from the unexplained but quantified residual variability. This is important as the WP calculation applies for a global “population of treated animals” and must include 99% of them. The prediction of WP was based on simulations taking into account IIV but not RV, because what is important is the actual concentration in tissue (which depends on IIV) and not the measured concentration (which depends also on RV). As there was only one tissue sample per animal (destructive sampling), IIV might be difficult to estimate and it is possible that RV, which was high for renal concentrations (57%), was inflated by unidentified IIV. This bias, resulting in an underestimation of the IIV, could result in an underestimation of the WP. On the other hand, VPCs indicated that there was a potential overestimation of the overall variability, without knowing if it was IIV or RV that was inflated: this bias would result in a contrary over-prediction of WP. This issue rises the necessity, for an accurate estimation of WP, of an accurate estimation of both IIV and RV. The NMLE approach is also efficient to handle sparse data (like in experiment n°4) and thus could limit the number of necessary animals. Furthermore, this method allows a sophisticated handling of data below the limit of quantification compared to the classic one. Indeed, in the latter approach, the rule is to omit or fix the data BLOQ at half of the LOQ but it could bias the results (22).

Lastly, it is necessary to highlight some analytical considerations. Due to the high instability of CMS, direct measure of its concentration was not possible (26). The indirect method used could not

discriminate renal CMS and colistin concentrations, which were pooled. Therefore, the estimations of parameters in kidney might have been biased. Moreover, CMS is a mixture of many methanesulfonated derivatives carrying various number of methanesulfonate groups (3). It was not possible to determine the concentration of each component separately; therefore, all these derivatives were considered as being CMS. As previously explained, colistin (which has no methanesulfonate group) is widely reabsorbed, whereas CMS (which have 5 methanesulfonate groups) is not. Therefore, some partially methanesulfonated derivatives, *i.e.* considered as CMS, might also be reabsorbed. These compounds may have an ADME closer to colistin than to CMS. All these concerns highlight the need of further analytical developments allowing to discriminate CMS and colistin in kidneys and to quantify the various methanesulfonate derivatives.

CONCLUSION

To conclude, this PBPK model coupled with a NMLE approach gave new insight into the mechanistic pharmacokinetics of CMS and colistin, especially within kidneys. This may have implications to limit the colistin induced-nephrotoxicity in human medicine. We also used this model to estimate withdrawal period in pigs treated with CMS, highlighting the utility of such an approach in veterinary medicine. Furthermore, PBPK models are helpful to perform inter-species extrapolation (from animal to human), but also intra-specie extrapolation (from adult to children). Thus, this model could be useful to adapt CMS dosing-regimen in pediatric population, a sub-population which is less studied. Some works about this topic are ongoing in our team.

Acknowledgments

Alexis Viel was supported by a doctoral fellowship from the French National Institute of Health and Medical Research (Inserm) and the French Agency for Food, Environmental and Occupational Health & Safety (Anses).

REFERENCES

1. Gregoire N, Aranzana-Climent V, Magreault S, Marchand S, Couet W. Clinical Pharmacokinetics and Pharmacodynamics of Colistin. *Clinical pharmacokinetics*. 2017.
2. Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. *The Journal of antimicrobial chemotherapy*. 2004;53(5):837-40.
3. Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K. Stability of Colistin and Colistin Methanesulfonate in Aqueous Media and Plasma as Determined by High-Performance Liquid Chromatography. *Antimicrobial Agents and Chemotherapy*. 2003;47(4):1364-70.
4. Forrest A, Garonzik SM, Thamlikitkul V, Giamarellos-Bourboulis EJ, Paterson DL, Li J, et al. Pharmacokinetic/toxicodynamic analysis of colistin-associated acute kidney injury in critically ill patients. *Antimicrobial Agents and Chemotherapy*. 2017:AAC. 01367-17.
5. Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. *Int J Antimicrob Agents*. 2005;25(1):11-25.
6. Couet W, Gregoire N, Gobin P, Saulnier P, Frasca D, Marchand S, et al. Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers. *Clinical Pharmacology & Therapeutics*. 2011;89(6):875-9.
7. Craig WA, Kunin CM. Dynamics of binding and release of the polymyxin antibiotics by tissues. *J Pharmacol Exp Ther*. 1973;184(3):757-65.
8. Tomasi L, Giovannetti L, Rondolotti A, Rocca GD, Stracciari GL. Depletion of the residues of colistin and amoxicillin in Turkeys following simultaneous subcutaneous administration. *Veterinary research communications*. 1996;20(2):175-82.
9. Ma Z, Wang J, Nation RL, Li J, Turnidge JD, Coulthard K, et al. Renal disposition of colistin in the isolated perfused rat kidney. *Antimicrobial agents and chemotherapy*. 2009;53(7):2857-64.
10. Suzuki T, Yamaguchi H, Ogura J, Kobayashi M, Yamada T, Iseki K. Megalin contributes to kidney accumulation and nephrotoxicity of colistin. *Antimicrobial agents and chemotherapy*. 2013;57(12):6319-24.
11. Yun B, Azad MA, Wang J, Nation RL, Thompson PE, Roberts KD, et al. Imaging the distribution of polymyxins in the kidney. *Journal of Antimicrobial Chemotherapy*. 2014:dku441.
12. Yun B, Azad MA, Nowell CJ, Nation RL, Thompson PE, Roberts KD, et al. Cellular uptake and localization of polymyxins in renal tubular cells using rationally designed fluorescent probes. *Antimicrobial agents and chemotherapy*. 2015;59(12):7489-96.
13. Azad MA, Roberts KD, Yu HH, Liu B, Schofield AV, James SA, et al. Significant accumulation of polymyxin in single renal tubular cells: a medicinal chemistry and triple correlative microscopy approach. *Analytical chemistry*. 2015;87(3):1590-5.
14. Lu X, Chan T, Xu C, Zhu L, Zhou QT, Roberts KD, et al. Human oligopeptide transporter 2 (PEPT2) mediates cellular uptake of polymyxins. *Journal of Antimicrobial Chemotherapy*. 2015.

15. Dai C, Li J, Tang S, Li J, Xiao X. Colistin-induced nephrotoxicity in mice involves the mitochondrial, death receptor, and endoplasmic reticulum pathways. *Antimicrob Agents Chemother.* 2014;58(7):4075-85.
16. Azad MA, Akter J, Rogers K, Nation RL, Velkov T, Li J. Major pathways of polymyxin-induced apoptosis in rat kidney proximal tubular cells. *Antimicrob Agents Chemother.* 2015.
17. Nestorov I. Whole-body physiologically based pharmacokinetic models. *Expert opinion on drug metabolism & toxicology.* 2007;3(2):235-49.
18. Bouchene S, Marchand S, Couet W, Friberg LE, Gobin P, Lamarche I, et al. Comparison of Colistin and Colistimethate sodium (CMS) Model-Predicted Whole-Body Distribution with Measured Tissue:Plasma Concentrations Ratios in Rats. 53 rd Interscience Conference on Antimicrobial Agents and Chemotherapy; Denver, CO2013.
19. Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters II. Biexponential model and experimental pharmacokinetic data. *Journal of Pharmacokinetics and Pharmacodynamics.* 1981;9(5):635-51.
20. Swindle MM, Makin A, Herron AJ, Clubb FJ, Frazier KS. Swine as Models in Biomedical Research and Toxicology Testing. *Veterinary Pathology Online.* 2012;49(2):344-56.
21. JECFA. Residue Evaluation of Certain Veterinary Drugs: Joint FAO/WHO Expert Committee on Food Additives, 66th Meeting 2006: Food & Agriculture Org.; 2006.
22. EMA. Guideline on approach towards harmonisation of withdrawal periods. European Medicines Agency (EMA) - Committee for Medicinal Products for Veterinary Use (CVMP), 2016 EMA/CVMP/CHMP/231573/2016 Contract No.: EMA/CVMP/SWP/735325/2012.
23. Lin Z, Gehring R, Mochel J, Lavé T, Riviere J. Mathematical modeling and simulation in animal health—Part II: principles, methods, applications, and value of physiologically based pharmacokinetic modeling in veterinary medicine and food safety assessment. *Journal of veterinary pharmacology and therapeutics.* 2016;39(5):421-38.
24. Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, et al. Consistent Global Approach on Reporting of Colistin Doses to Promote Safe and Effective Use. *Clinical Infectious Diseases.* 2014;58(1):139-41.
25. Rottbøll LAH, Friis C. Penetration of antimicrobials to pulmonary epithelial lining fluid and muscle and impact of drug physicochemical properties determined by microdialysis. *Journal of pharmacological and toxicological methods.* 2016;78:58-65.
26. Gobin P, Lemaître F, Marchand S, Couet W, Olivier J-C. Assay of Colistin and Colistin Methanesulfonate in Plasma and Urine by Liquid Chromatography-Tandem Mass Spectrometry. *Antimicrobial Agents and Chemotherapy.* 2010;54(5):1941-8.
27. Buur JL, Baynes RE, Craigmill AL, Riviere JE. Development of a physiologic-based pharmacokinetic model for estimating sulfamethazine concentrations in swine and application to prediction of violative residues in edible tissues. *American journal of veterinary research.* 2005;66(10):1686-93.
28. Chen K, Seng KY. Calibration and validation of a physiologically based model for soman intoxication in the rat, marmoset, guinea pig and pig. *Journal of applied toxicology : JAT.* 2012;32(9):673-86.
29. de Boer VC, Dihal AA, van der Woude H, Arts IC, Wolfram S, Alink GM, et al. Tissue distribution of quercetin in rats and pigs. *The Journal of nutrition.* 2005;135(7):1718-25.
30. Dubbelboer IR, Lilienberg E, Sjögren E, Lennernas H. A model-based approach to assessing the importance of intracellular binding sites in doxorubicin disposition. *Molecular Pharmaceutics.* 2017;14(3):686-98.
31. Elowsson P, Carlsten J. Body composition of the 12-week-old pig studied by dissection. *Laboratory animal science.* 1997;47(2):200-2.
32. Eskild-Jensen A, Jacobsen L, Christensen H, Frokiaer J, Jorgensen HS, Djurhuus JC, et al. Renal function outcome in unilateral hydronephrosis in newborn pigs. II. Function and volume of contralateral kidneys. *J Urol.* 2001;165(1):205-9.

33. Lødrup AB, Karstoft K, Dissing TH, Nyengaard JR, Pedersen M. The association between renal function and structural parameters: a pig study. *BMC Nephrology*. 2008;9:18-.
34. Lundeen G, Manohar M, Parks C. Systemic distribution of blood flow in swine while awake and during 1.0 and 1.5 MAC isoflurane anesthesia with or without 50% nitrous oxide. *Anesthesia and analgesia*. 1983;62(5):499-512.
35. Rendas A, Branthwaite M, Reid L. Growth of pulmonary circulation in normal pig--structural analysis and cardiopulmonary function. *Journal of Applied Physiology*. 1978;45(5):806-17.
36. Scotcher D, Jones C, Posada M, Rostami-Hodjegan A, Galetin A. Key to Opening Kidney for In Vitro-In Vivo Extrapolation Entrance in Health and Disease: Part I: In Vitro Systems and Physiological Data. *The AAPS journal*. 2016;18(5):1067-81.
37. Suenderhauf C, Parrott N. A physiologically based pharmacokinetic model of the minipig: data compilation and model implementation. *Pharmaceutical research*. 2013;30(1):1-15.
38. Ten have GAM, Bost MCF, Suyk-Wierts JCAW, van den Bogaard AEJM, Deutz NEP. Simultaneous measurement of metabolic flux in portally-drained viscera, liver, spleen, kidney and hindquarter in the conscious pig. *Laboratory Animals*. 1996;30(4):347-58.
39. Tranquilli WJ, Manohar M, Parks CM, Thurmon JC, Theodorakis MC, Benson GJ. Systemic and regional blood flow distribution in unanesthetized swine and swine anesthetized with halothane + nitrous oxide, halothane, or enflurane. *Anesthesiology*. 1982;56(5):369-79.
40. Upton RN. Organ weights and blood flows of sheep and pig for physiological pharmacokinetic modelling. *Journal of Pharmacological and Toxicological Methods*. 2008;58(3):198-205.
41. Vinegar A. Development of a physiologically based pharmacokinetic model for the anesthetics halothane, isoflurane, and desflurane in the pig (*Sus scrofa*). DTIC Document, 1999.
42. Drougas JG, Barnard SE, Wright JK, Sika M, Lopez RR, Stokes KA, et al. A model for the extended studies of hepatic hemodynamics and metabolism in swine. *Laboratory animal science*. 1996;46(6):648-55.
43. Peters SA. Physiologically-based pharmacokinetic (PBPK) modeling and simulations: principles, methods, and applications in the pharmaceutical industry: John Wiley & Sons; 2012.
44. Scotcher D, Jones C, Rostami-Hodjegan A, Galetin A. Novel minimal physiologically-based model for the prediction of passive tubular reabsorption and renal excretion clearance. *European Journal of Pharmaceutical Sciences*. 2016;94:59-71.
45. Leavens T, Tell L, Clothier K, Griffith R, Baynes RE, Riviere J. Development of a physiologically based pharmacokinetic model to predict tulathromycin distribution in goats. *Journal of veterinary pharmacology and therapeutics*. 2012;35(2):121-31.
46. Dosne A-G, Bergstrand M, Harling K, Karlsson MO. Improving the estimation of parameter uncertainty distributions in nonlinear mixed effects models using sampling importance resampling. *Journal of pharmacokinetics and pharmacodynamics*. 2016;43(6):583-96.
47. Karlsson MO, Beal SL, Sheiner LB. Three new residual error models for population PK/PD analyses. *Journal of Pharmacokinetics and Pharmacodynamics*. 1995;23(6):651-72.
48. Beal SL. Ways to fit a PK model with some data below the quantification limit. *Journal of pharmacokinetics and pharmacodynamics*. 2001;28(5):481-504.
49. Chevance A, Jacques AM, Laurentie M, Sanders P, Henri J. The present and future of withdrawal period calculations for milk in the European Union: focus on heterogeneous, nonmonotonic data. *Journal of veterinary pharmacology and therapeutics*. 2017;40(3):218-30.
50. Lindbom L, Pihlgren P, Jonsson N. PsN-Toolkit—a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. *Computer methods and programs in biomedicine*. 2005;79(3):241-57.
51. Keizer RJ, Van Benten M, Beijnen JH, Schellens JH, Huitema AD. Pirana and PCluster: a modeling environment and cluster infrastructure for NONMEM. *Computer methods and programs in biomedicine*. 2011;101(1):72-9.
52. Landersdorfer CB, Nguyen T-H, Lieu LT, Nguyen G, Bischof RJ, Meeusen EN, et al. Substantial Targeting Advantage Achieved by Pulmonary Administration of Colistin Methanesulfonate in a Large-Animal Model. *Antimicrobial agents and chemotherapy*. 2017;61(1):e01934-16.

53. Karvanen M, Malmberg C, Lagerback P, Friberg LE, Cars O. Colistin Is Extensively Lost during Standard In Vitro Experimental Conditions. *Antimicrob Agents Chemother*. 2017;61(11).
54. Huang JX, Blaskovich MA, Pelingon R, Ramu S, Kavanagh A, Elliott AG, et al. Mucin binding reduces colistin antimicrobial activity. *Antimicrobial agents and chemotherapy*. 2015;59(10):5925-31.
55. Hinderling PH. Red blood cells: a neglected compartment in pharmacokinetics and pharmacodynamics. *Pharmacological reviews*. 1997;49(3):279-95.
56. Azad MA, Huang JX, Cooper MA, Roberts KD, Thompson PE, Nation RL, et al. Structure–activity relationships for the binding of polymyxins with human α -1-acid glycoprotein. *Biochemical pharmacology*. 2012;84(3):278-91.
57. Bouchene S, Marchand S, Friberg LE, Björkman S, Couet W, Karlsson MO, editors. Whole Body Physiologically-Based Pharmacokinetic Model for Colistin and Colistimethate Sodium (CMS) in Six Different Species: Mouse, Rat, Rabbit, Baboon, Pig and Human. *Journal of Pharmacokinetics and Pharmacodynamics*; 2013.
58. Holford NH, Anderson BJ. Allometric size: The scientific theory and extension to normal fat mass. *European Journal of Pharmaceutical Sciences*. 2017.
59. Yousef JM, Chen G, Hill PA, Nation RL, Li J. Melatonin attenuates colistin-induced nephrotoxicity in rats. *Antimicrobial agents and chemotherapy*. 2011;55(9):4044-9.
60. Zavascki AP, Nation RL. Nephrotoxicity of polymyxins: Is there any difference between colistimethate and polymyxin B? *Antimicrobial Agents and Chemotherapy*. 2016.
61. Manchandani P, Zhou J, Babic JT, Ledesma KR, Truong LD, Tam VH. The role of renal drug exposure in polymyxin B-induced nephrotoxicity. *Antimicrobial Agents and Chemotherapy*. 2017:AAC. 02391-16.
62. Vardakas KZ, Falagas ME. Colistin versus polymyxin B for the treatment of patients with multidrug-resistant Gram-negative infections: a systematic review and meta-analysis. *International Journal of Antimicrobial Agents*. 2016.
63. Ordooei Javan A, Shokouhi S, Sahraei Z. A review on colistin nephrotoxicity. *European journal of clinical pharmacology*. 2015.
64. Li M, Gehring R, Riviere JE, Lin Z. Development and application of a population physiologically based pharmacokinetic model for penicillin G in swine and cattle for food safety assessment. *Food and Chemical Toxicology*. 2017;107:74-87.
65. EMA. Updated advice on the use of colistin products in animals within the European Union: development of resistance and possible impact on human and animal health. European Medicines Agency (EMA), 2016 EMA/CVMP/CHMP/231573/2016.

Legend to Figures

Figure 1: A global diagram of the physiologically based pharmacokinetic (PBPK) model of CMS and colistin in swine.

The whole body PBPK model is described (A), as well as the detailed mechanism in a generic tissue (except kidneys) (B), of the IM route (C) and of the deep compartments (D).

891 During model development, supplementary components were added in the final model and are
892 represented in blue (see Results). Kidney sub-compartments and urine are detailed in Fig. 2. All
893 estimated parameters (in italic) are detailed in Table IV.

894 V_{tissue} : tissue volume; Q_{tissue} : blood flow; K_p : partition coefficient; IV: intravenous dose; IM:
895 intramuscular dose

896

897

898 Figure 2: Schematic representation of the renal sub-compartments in the PBPK model of CMS and
899 colistin in swine.

900 All estimated parameters (in italic) are detailed in Table IV.

901 During model development, supplementary components were added in the final model and are
902 represented in blue (see Results).

903 Q_{KID} : renal blood flow; Q_{URI} : urinary flow; Q_{TUB} : tubular flow; $CL_{\text{GFR_CMS}}/CL_{\text{GFR_COLI}}$: filtration
904 clearance of CMS and colistin

905 Figure 3: Visual Predictive Checks of the PBPK model for CMS and colistin plasma concentrations
906 after one IV (A) and one IM (B) of CMS, used for model calibration.

907 Plasma data come from experiment n°1 for A (125,000 UI/kg of CMS after IV infusion over 1h) and
908 from experiment n°2 for B (125,000 UI/kg of CMS after IM injection).

909 Blue dots represent the observed plasma concentrations; the grey areas represent the 90%
910 prediction interval of the model, whereas the black solid line represents the median; the purple area
911 represents the 95% confidence interval around the median; the horizontal dashed black lines
912 represent the LOQ. In the smaller panels, blue areas represent the simulation-based 95% confidence
913 intervals for the fraction of model simulated samples below the LOQ (BLOQ) at each time point,
914 whereas the blue solid line represents the actual observed fraction of BLOQ samples.

915

916 Figure 4: Visual Predictive Checks of the PBPK model for CMS and colistin plasma concentrations
917 after a dosing scheme to achieve steady-state (A) and repeated IM administrations (B) of CMS, used
918 for model calibration.

919 Plasma data come from experiment n°3 for A (75,000 UI/kg IV during 1 h; 1.5 h without
920 administration; 50,000 UI/kg IV during 4 h) and from experiment n°4 for B (50,000 UI/kg of CMS
921 divided in two IM injection per day).

922 Blue dots represent the observed plasma concentrations; the grey areas represent the 90%
923 prediction interval of the model, whereas the black solid line represents the median; the purple area

represents the 95% confidence interval around the median; the horizontal dashed black lines represent the LOQ.

No data below LOQ (BLOQ) were observed in A. For B, fractions of BLOQ are not represented due to the sparse sampling but they are discussed in the text.

Figure 5: Visual Predictive Checks of the PBPK model for cumulative urinary quantities concentrations after one IV of CMS, used for model calibration.

Urinary data come from experiment n°1 (125,000 UI/kg of CMS after IV infusion over 1h).

Blue dots represent the observed plasma concentrations; the grey area represents the 90% prediction interval of the model, whereas the black solid line represents the median. The purple area represents the 95% confidence interval around the median;

Figure 6: Visual Predictive Checks of the PBPK model for total renal concentrations after one IV (A), the dosing scheme of infusions for steady-state (B) and repeated IM administrations (C) of CMS, used for model calibration.

Kidney data come from experiment n°1 for A (125,000 UI/kg of CMS after IV infusion over 1h); from experiment n°3 for B (75,000 UI/kg IV during 1 h; 1.5 h without administration; 50,000 UI/kg IV during 4 h, those pigs received one IV and one IM, 48h and 24h before t=0h, respectively) and from experiment n°4 for C (50,000 UI/kg of CMS divided in two IM injection per day).

Blue dots represent the observed plasma concentrations; the grey areas represent the 90% prediction interval of the model, whereas the black solid line represents the median. The purple area represents the 95% confidence interval around the median. No data were below the LOQ (0.15 µg/g).

Figure 7: VPC of the PBPK model for CMS (A) and colistin (B) plasma concentrations after 3 days of IM administrations of CMS, used for model validation.

Observed data come from an independent experiment (n°5: 50,000 UI/kg of CMS divided in two IM injection per day during 3 days) that was not used for model calibration.

Blue dots represent the observed plasma concentrations; the grey areas represent the 90% prediction interval of the model, whereas the black solid line represents the median; the purple area represents the 95% confidence interval around the median ; the horizontal dashed black lines represent the LOQs. In the smaller panels, blue areas represent the simulation-based 95% confidence intervals for the fraction of model-simulated samples below the LOQ (BLOQ) at each time point, whereas the blue solid line represents the actual observed fraction of BLOQ samples.

Figure 8: VPC of the PBPK model for total renal concentrations after 3 days of IM administrations of CMS. Observed data come from an independent experiment (n°5: 50,000 UI/kg of CMS divided in two IM injection per day) that was not used for model calibration.

Blue dots represent the observed plasma concentrations; highlighted with grey are the areas between the 5th and 95th percentiles of model simulations, whereas the black solid line represents the median. No data were below the LOQ (0.15 µg/g).

Figure 9: CMS and colistin disposition within kidneys as given by the PBPK model.

Each percentage represents the fraction of the initial dose (100%) involved in each process.

$f u_{CMS} / f u_{COLI}$: unbound fraction of CMS/colistin; GFR: glomerular filtration rate

Figure 10: Withdrawal period estimation in a 50-kg pig.

Model simulation in kidney after 3 consecutive days of CMS IM injections (50,000 UI/kg of CMS divided in two injections per day) for 1000 virtual pigs of 50 kg.

The grey area includes the 1st and 99th percentiles of model simulations, whereas the black solid line represents the median; the horizontal dashed black line represents the kidney MRL for colistin (0.20 µg/g).

WP: withdrawal period, rounded to the next whole day

TABLES

Table I: Summary of pharmacokinetic experimental studies of CMS and colistin in swine used for calibration and validation of the PBPK model

Modelling purpose	N° of experiment	Route	Dose of CMS (UI/kg)	Number of pigs	Number of doses	Numbers of samples per pig (min-max)
CALIBRATION	1	IV	125,000 (1 h- infusion)	10	1	Blood: 12 Urine: (2-9) Kidneys: 1
	2	IM	125,000	6	1	Blood: 12
	3	IV	75,000 during 1 h; 1.5 h without administration; 50,000 during 4 h	6	1	Blood: (1-4) All organs: 1
	4	IM	50,000 (divided in two administrations of 2 per day)	15	7 maximum (i.e. 14 injections)	Blood: (1-4) Kidneys: 1
VALIDATION	5	IM	50,000 (divided in two administrations of 2 per day)	20	3 (i.e. 6 injections)	Blood: 1 Kidneys, fat, skin, liver, muscles: 1

Notes: The abbreviations for the route: IM, intramuscular injection; IV, intravenous injection. Some pigs were used in different experiments (n°1, 2 and 3) in model calibration.

Table II: physiological and *chemical*-specific parameters for PBPK model

Compartments	Volume (fraction of BW)	References	Blood flow (fraction of CO)	References
Arterial blood	0.027	(28, 41)	1	-
Venous blood	0.053	(28, 41)	1	-
Lung	0.027	(35)	1	-
Brain	0.0034	(31, 39, 41)	0.02	(39, 40)
Heart	0.0062	(31, 41)	0.037	(29, 30)
Muscles	0.38	(31, 40)	0.2	(34, 40, 41)
Skin	0.077	(31, 41)	0.05	(37)
Adipose	0.18	(31, 41)	0.17	(34, 40)
GIT	0.062	(31, 39, 40)	0.22	(38, 39)
Liver	0.027	(31, 39, 41)	Hepatic artery + GIT blood flow : 0.27	(34, 38, 39)
Kidneys	0.0048	(31, 41)	0.13	(38-40)
Vascular	0.067 ^a	(27, 29)	-	-
Extravascular	0.12 ^a	(30)	-	-
Tubular lumen	0.2 ^{a,b}	(36)	-	-
Intracellular	0.613 ^{a,c}		-	-
Bladder	0.01 ^d	-	-	-
Rest of Body	0.14 ^e	-	0.12 ^f	-
TOTAL	1	-	1	-
Other parameters (units)	Value	References		
Cardiac output ^g (L/h/kg)	8.5	(27, 39, 40)		
Haematocrit	0.40	(42)		
GFR (L/h/kg)	0.074	(32, 33)		
Urinary flow (L/h/kg)	0.0022	Experimental data		
Tubular flow (L/h/kg)	67% of GFR	(36)		
Colistin partition coefficient (Kp)	Mean value +/- SD (unitless)	References		
Lung	0.73 ± 0.31	Experimental data		
Brain	0.71 ± 0.37			
Heart	0.29 ± 0.14			
Muscles	0.10 ± 0.029			
Skin	0.43 ± 0.17			
Adipose	0.25 ± 0.11			
GIT	0.41 ± 0.17			
Liver	0.52 ± 0.26			
Kidneys	NC	-		
Rest of body	0.4	Fixed to the mean of others Kps		
Unbound fraction CMS	0.37	Experimental data (see Table III)		
Unbound fraction colistin	0.40	(25)		

^a defined as fraction of kidney volume; ^b fixed to human value; ^c calculated by subtracting all fractions of the 3 other sub-compartments; ^d arbitrary fixed; ^e calculated by subtracting all fractions of the other organs; ^f calculated by subtracting all fractions of the other organs except arteries, veins and lung; ^g Cardiac output was multiplied by (1 – haematocrit) to get the total plasmatic flow

NC : not concerned ; GFR : glomerular filtration rate ; GIT : gastro-intestinal tract

Table III: Results of experiments for the determination of plasmatic unbound fraction of CMS in pigs (n=3)

Theoretical CMS concentration in parent solution (µg/mL)	Media	Measured CMS concentration in parent solution (µg/mL)	CMS concentration in ultrafiltrate (µg/mL)	Fraction of loss	Unbound fraction
5	Phosphate buffer	6.3	4.5 ± 0,5	28%	NC
5	Pig plasma	4.4	1.2 ± 0.12	73%	0.38 ± 0.04 ^a
0.5		0.49	0.12 ± 0.01	75%	0.36 ± 0.02 ^a

^a: Calculated accounting for the loss due to the CMS degradation (hydrolysis) and the non-specific binding to the tube determined in phosphate buffer; NC : not concerned

Table IV: CMS and colistin parameters optimised in the PBPK model

Parameters (unit)	Value [CI 95%]	IIV [CI 95%]	Meaning
CMS			
K_{hyd_CMS} (h ⁻¹)	0.262 [0.238-0.290]	-	CMS hydrolysis constant (common for all compartments)
K_{IM_CMS} (h ⁻¹)	1.78 [1.39-2.35]	-	Absorption constant of CMS for intra-muscular route
Kp_{mix_CMS} (unitless)	0.217 [0.189-0.242]	-	Kp of CMS compartments (common for all compartments)
CL_{sec_CMS} (L.h ⁻¹)	8.39 [6.53-10.94]	0.193 (43.5%) [0.0840-0.403]	Tubular CMS secretion from kidney vascular space to tubular lumen
Colistin			
K_{deg_COLI} (h ⁻¹)	0.389 [0.334-0.456]	0.0737 (26.6%) [0.0437-0.139]	Colistin non-renal eliminating constant (common for all compartments)
K_{IM_COLI} (h ⁻¹)	5.99 [3.09-13.77]	-	Absorption constant of colistin for intra-muscular route
K_{DEEP_COLI} (h ⁻¹)	0.187 [0.135-0.295]	-	Transfer constant of colistin from vascular compartments towards deep compartment
$K_{DEEP_OUT_COLI}$ (h ⁻¹)	0.104 [0.0670-0.149]	-	Transfer constant of colistin from deep compartment towards vascular compartments
K_{ON_COLI} (h ⁻¹)	0.0910 [0.0524-0.157]	-	“Binding” constant of colistin in kidney intracellular compartments
K_{OFF_COLI} (h ⁻¹)	0.0145 [0.0051-0.0230]	-	“Unbinding” constant of colistin in kidney intracellular compartments
CL_{reabs_COLI} (L.h ⁻¹)	106 (fixed)	-	Reabsorption of colistin tubular lumen into intracellular compartment
Residual errors (proportional)			
RV_{plas_CMS}	0.171 (41 %) [0.136-0.225]	-	Proportional residual error for plasmatic CMS concentrations
RV_{plas_COLI}	0.166 (41 %) [0.136-0.205]	-	Proportional residual error for plasmatic colistin concentrations
Common RV term of CMS and colistin in plasma	0.0824 [0.0541-0.116]	-	L2 data item method
RV_{tissue_CMS}	0.111 (33 %) [0.0644-0.192]	-	Proportional residual error for the tissue CMS concentrations
RV_{KID}	0.331 (57 %) [0.193-0.574]	-	Proportional residual error for kidney total concentrations
RV_{URINE}	0.258 (51 %) [0.171-0.402]	-	Proportional residual error for urinary total concentrations

IIV: inter-individual variability; CI: confidence interval

Table V: Results of the local sensitivity analysis

Estimated parameters	Impact of a +10% in value on output ^a (in % of variation)	Impact of a -10% in value on output ^a (in % of variation)
CMS		
K_{hyd_CMS}	1.09	0.67
K_{IM_CMS}	0.22	0.40
K_{pmix_CMS}	0.54	0.44
CL_{sec_CMS}	0.54	0.66
Colistin		
K_{deg_COLI}	4.59	5.45
K_{IM_COLI}	< 0.1	< 0.1
K_{BIND_COLI}	< 0.1	< 0.1
$K_{BIND_OUT_COLI}$	< 0.1	< 0.1
K_{ON_COLI}	2.95	3.50
K_{OFF_COLI}	8.29	9.05
CL_{reabs_COLI}	< 0.1	< 0.1

^aThe output is the time when the median model prediction of the kidney concentration crossed the corresponding MRL. In bold are the parameters that are the most influential for output. All parameters are detailed in Table IV.

Fig. 1

A

B

C

D

Fig. 2

Fig. 3

A

B

Fig. 4**A** **B**

Fig. 5

Fig. 6

Fig. 7

A

B

Fig. 8

Tubular lumen

Fig. 9

CMS 100% **colistin** 100%

$fu_{CMS} \cdot GFR$
~12%

$fu_{COLI} \cdot GFR$
~18%

*Glomerular
filtration*

**Vascular
space**

Reabsorption
~18%

Intra-
cellular
colistin

Degradation
~18%

*Hydrolysis
into colistin* <1%

Tubular secretion
~56%

~68% <0.5%

URINE

Tubular cell

~32% ~82%

Fig. 10

Supplementary figures legend

Figure S1: Goodness-of-fit plots for model validation

Population predicted (PRED) versus observed concentrations or quantities (DV) in log-log scale (A) and linear scale (B).

Individual predicted (PRED) versus observed concentrations or quantities (DV) in log-log scale (C) and linear scale (D).

Figure S2: Visual Predictive Checks of the PBPK model for colistin tissue data in liver (A), muscles (B), skin (C), fat (D), used for model validation.

Observed data come from an independent experiment ($n=5$: 50,000 UI/kg of CMS divided in two IM injection per day during 3 days) that was not used for model calibration.

Blue dots represent the observed tissue concentrations; highlighted with grey are the areas between the 5th and 95th percentiles of model simulations, whereas the black solid line represents the median; the purple area represents the 95% confidence interval around the median; the horizontal dashed black line represents the LOQ. In the lower panels, blue areas represent the simulation-based 95% confidence intervals for the fraction of data below the LOQ (BLOQ), whereas the blue solid line represents the actual observed fraction of BLOQ samples.

Figure S3: Visual Predictive Checks of the PBPK model for CMS tissue data in liver (A), muscles (B), skin (C), fat (D), used for model validation.

Observed data come from an independent experiment ($n=5$: 50,000 UI/kg of CMS divided in two IM injection per day during 3 days) that was not used for model calibration.

Blue dots represent the observed tissue concentrations; highlighted with grey are the areas between the 5th and 95th percentiles of model simulations, whereas the black solid line represents the median; the purple area represents the 95% confidence interval around the median; the horizontal dashed black line represents the limit of quantification. In the lower panels, blue areas represent the simulation-based 95% confidence intervals for the fraction of data below the LOQ (BLOQ), whereas the blue solid line represents the actual observed fraction of BLOQ samples.

Figure S4: Relative contribution of CMS and colistin in total kidney concentrations.

CMS concentrations (green), colistin concentrations (red) and total concentrations in kidney after one IV of CMS (10 mg/kg) for a 50-kg pig.

Figure S5: Evolution of the mass balance predicted by the model after one IV of CMS, as expressed in relative quantities for CMS (A) and colistin (B) in each compartment.

GIT : gastro-intestinal tract

Figure S6: Withdrawal period estimation in a 100-kg pig

Model simulation in kidney after 3 consecutive days of CMS IM injections (50,000 UI/kg of CMS divided in two injections per day) for 1000 virtual pigs of 100 kg.

The grey area includes the 1st and 99th percentiles of model simulations, whereas the black solid line represents the median; the horizontal dashed black line represents the kidney MRL (0.20 µg/g).

WP: withdrawal period, rounded to the next whole day

Fig. S2

Fig. S3**A** **B** **C** **D**

Fig. S4

Fig. S5

Fig. S6

```

1
2 ;; 1. Based on: Z80
3 ;; 2. Description: LN : modèle PBPK CMS/coli
4 ;; x1. Author: user
5 ;; 3. Label:
6
7 $SIZES      PC=46 PDT=210 LVR=66 LVR2=42 LNP4=10000
8 $PROBLEM    PBPK
9 $INPUT      ID TIME CMT DV AMT RATE LLOQ UVOL EVID MDV WT OCC=DROP L2
10            STU=DROP
11 $DATA       dataset.csv IGNORE=#
12 $SUBROUTINE ADVAN14 TOL=6
13 $MODEL      COMP=(Aven1) ; venous blood (CMS)
14            COMP=(Aart1) ; arterial blood (CMS)
15            COMP=(Alun1) ; lung (CMS)
16            COMP=(Abral) ; brain (CMS)
17            COMP=(Ahrt1) ; heart (CMS)
18            COMP=(Amus1) ; muscle (CMS)
19            COMP=(Askn1) ; skin (CMS)
20            COMP=(Aadi1) ; adipose (CMS)
21            COMP=(Ahep1) ; liver (CMS)
22            COMP=(Agiol) ; gut (CMS)
23            COMP=(Akidmix1) ; kidney vascular compartment (CMS)
24            COMP=(Atub1) ; Kidney tubules (CMS)
25            COMP=(AkidEV1) ; kidney extra-vascular compartment (CMS)
26            COMP=(Akidcell) ; kidney (intra)cellular compartment (CMS)
27            COMP=(Avessiel) ; bladder CMS
28            COMP=(Aurl) ; urine (CMS)
29            COMP=(Ares1) ; rest of body (CMS)
30            COMP=(depCMS) ; IM depot compartment (CMS)
31
32            COMP=(Aven2) ; venous blood (colistin)
33            COMP=(Aart2) ; arterial blood (colistin)
34            COMP=(Abra2) ; brain (colistin)
35            COMP=(Alun2) ; lung (colistin)
36            COMP=(Ahrt2) ; heart (colistin)
37            COMP=(Amus2) ; muscle (colistin)
38            COMP=(Askn2) ; skin (colistin)
39            COMP=(Aadi2) ; adipose (colistin)
40            COMP=(Ahep2) ; liver (colistin)
41            COMP=(Agiol2) ; gut (colistin)
42            COMP=(Akidmix2) ; kidney vascular (colistin)
43            COMP=(Atub2) ; Kidney tubule (colistin)
44            COMP=(AkidEV2) ; kidney extra-vascular compartment (colistin)
45            COMP=(Akidcel2) ; kidney (intra)cellular compartment (colistin)
46            COMP=(Akiideep2) ; kidney binding compartment (colistin)
47            COMP=(Avessie2) ; bladder (colistin)
48            COMP=(Aur2) ; urine (colistin)
49            COMP=(Ares2) ; rest of body (colistin)
50            COMP=(depColi) ; IM depot compartment (colistin)
51            COMP=(AdeepV2) ; colistin vein deep compartment
52            COMP=(AdeepA2) ; colistin artery deep compartment
53
54            COMP=(Elimccol) ; colistin elimination by metabolism (for mass balance)
55
56 $PK
57 ;; ----- Parameters ----- ;;
58
59
60 TVKHYD = THETA(1)
61 MU_1 = LOG(TVKHYD) ;
62 KHYD = EXP(MU_1+ETA(1)) ;; hydrolysis constant of CMS into colistin
63
64 TVKNR = THETA(2)
65 MU_2 = LOG(TVKNR) ;
66 KNR = EXP(MU_2+ETA(2)) ; degradation constant of colistin
67
68 TVfu_cms = THETA(3)
69 MU_3 = LOG(TVfu_cms) ;
70 fu_cms = EXP(MU_3+ETA(3)) ; Unbound fraction CMS ; NOT ESTIMATED
71
72
73 TVfu_coli = THETA(4)

```

```

74 MU_4 = LOG(TVfu_coli)
75 fu_coli = EXP(MU_4+ETA(4)) ; Unbound fraction colistin ; NOT ESTIMATED
76
77 TVKres2 = THETA(5)
78 MU_5 = LOG(TVKres2) ;
79 Kres2 = EXP(MU_5+ETA(5)) ; Kp of rest of body (colistin) ; NOT
ESTIMATED
80
81 TVka1 = THETA(6)
82 MU_6 = LOG(TVka1)
83 ka1 = EXP(MU_6+ETA(6)) ; Absorption constant of CMS for intra-muscular route
84
85 TVka2 = THETA(7)
86 MU_7 = LOG(TVka2) ;
87 ka2 = EXP(MU_7+ETA(7)) ; Absorption constant of colistin for
intra-muscular route
88
89
90 TVKNRcel = THETA(8)
91 MU_8 = LOG(TVKNRcel) ;
92 KNRcel = EXP(MU_8+ETA(8)) ; ; NOT USED
93
94 TVKmix1= THETA(9)
95 MU_9 = LOG(TVKmix1) ;
96 Kmix1 = EXP(MU_9+ETA(9)) ; Kp of CMS compartments (common for all
compartments)
97
98 TVkb2 = THETA(10)
99 MU_10 = LOG(TVkb2) ;
100 kb2 = EXP(MU_10+ETA(10)) ; "Binding" constant of colistin in vascular
compartments
101
102 TVkb2_out = THETA(11)
103 MU_11 = LOG(TVkb2_out) ;
104 kb2_out = EXP(MU_11+ETA(11)) ; "Unbinding" constant of colistin in vascular
compartments
105
106
107 TVk_on2= THETA(12)
108 MU_12 = LOG(TVk_on2) ;
109 k_on2 = EXP(MU_12+ETA(12)) ; "Binding" constant of colistin in kidney
intracellular compartments
110
111
112 TVk_off2 = THETA(13)
113 MU_13 = LOG(TVk_off2) ;
114 k_off2 = EXP(MU_13+ETA(13)) ; "Unbinding" constant of colistin in kidney
intracellular compartments
115
116
117 TVCLreab2= THETA(14)
118 MU_14 = LOG(TVCLreab2) ;
119 CLreab2 = EXP(MU_14+ETA(14)) ; Reabsorption of colistin tubular lumen into
intracellular compartment ; NOT ESTIMATED
120
121
122 TVKCLsec1= THETA(15)
123 MU_15 = LOG(TVKCLsec1) ;
124 CLsec1 = EXP(MU_15+ETA(15)) ; Tubular CMS secretion from kidney vascular space
to tubular lumen
125
126
127
128
129
130
131
132
133
134 ;; ----- Tissue volumes (L) ----- ;;
135
136
137 Vart = (2.65/100) *WT ; Arterial volume (L);

```

```

138 Vven = (5.3/100) * WT                ;; Venous volume (L);
139 Vlung = (2.7/100) * WT                ; Lung volume (L);
140 Vbra = (0.34/100)* WT                ; Brain volume (L);
141 Vhrt = (0.62/100)* WT                ; Heart volume (L);
142 Vmus = (37.8/100)*WT                ;; Muscle volume (L)
143 Vskn = (7.7/100)*WT                ;; Skin volume (L);
144 Vadi = (17.7/100) * WT                ;; Adipose volume (L);
145 Vhep = (2.7/100)* WT                ; Liver volume (L);
146 Vgio = (6.18/100)*WT                ;; GIO volume stomach+Small Intestine+colon (L);
147 Vkid = (0.48/100) * WT                ; Kidney volume (L);
148 Vkidmix = (6.7/100) * Vkid            ; Vascular fraction of Kidney
149 VkidEV = (11.8/100) * Vkid            ; extra-Vascular fraction of Kidney
150 Vtub = (20/100)*Vkid                ; Tubulear fraction of Kidney
151 Vvessie = 0.01*WT                ; Bladder volume
152 Vkidcel = Vkid- (Vkidmix + VkidEV+Vtub) ; Cellular fraction of Kidney
153
154 Vres = WT - (Vart + Vven + Vlung + Vbra+ Vhrt + Vskn + Vmus + Vadi + Vgio + Vhep +
Vkid+Vvessie)                ;; Rest of body volume
155
156 Vtot = WT                            ; Total Volume
157
158
159 ;; ----- Blood flows (L/H) ----- ;;
160 deb = 8.5                            ; cardiac output (L/h/kg)
161 Ht = 0.35                            ; Pig hematocrit
162 CO = deb * WT * (1-Ht)                ; Total plasmatic flow (L/h)
163
164 GFR = 0.074 * WT                    ; Glomerular filtration rate (L/h)
165
166
167 Qbra = (2.05/100) * CO                ;; Brain plasmatic flow (L/h)
168 Qhrt = (3.67/100) * CO                ;; Heart plasmatic flow (L/h)
169 Qskn = (5/100) * CO                  ; ; Skin plasmatic flow (L/h)
170 Qmus = (20/100)*CO                    ;; Muscle plasmatic flow(L/h)
171 Qadi = (16.7/100)*CO                ;; Adipose plasmatic flow (L/h)
172 Qgio = (21.5/100)*CO                ;; GIO plasmatic flow (L/h)
173 QhepArt = (5.1/100)*CO                ; ; Hepatic arterial plasmatic flow (L/h)
174 QhepT= QhepArt + Qgio                ; ; Total hepatic plasmatic flow (L/h)
175 Qkid = (13.45/100)*CO                ; ; Kidney plasmatic flow (L/h)
176 Qtub = 0.67*GFR                    ; ; Tubular flow in kidney (L/h)
177 Quri = 0.0022 * WT                  ; urinary flow, experimental data (L/h)
178
179 SUMQ = Qmus + Qkid + Qhrt + QhepT + Qbra + Qskn + Qadi
180 Qres = CO - SUMQ                    ;rest of body plasmatic flow (L/h)
181
182 Qart = CO                            ; ; Artery plasmatic flow
183 Qlung = CO                            ; ; Lung plasmatic flow
184 Qven = CO                            ; ; Vein plasmatic flow
185
186
187 ;; ----- Partition Coefficients ----- ;;
188
189 ;-----Kp CMS-----;
190
191 ; estimated
192
193 ;-----Kp Colistin-----;
194
195 Klun2 = 0.73 * EXP(ETA(16))            ; Lung Kp (experimentally determined)
196 Kbra2 = 0.71 * EXP(ETA(17))            ; brain Kp (experimentally determined)
197 Khrt2 = 0.29 * EXP(ETA(18))            ; heart Kp (experimentally determined)
198 Kskn2 = 0.43 * EXP(ETA(19))            ; skin Kp (experimentally determined)
199 Kmus2 = 0.10 * EXP(ETA(20))            ; muscles Kp (experimentally determined)
200 Kadi2 = 0.25 * EXP(ETA(21))            ; Adipose Kp (experimentally determined)
201 Kgio2 = 0.41 * EXP(ETA(22))            ; GIO Kp (experimentally determined)
202 Khep2 = 0.52 * EXP(ETA(23))            ; Liver Kp (experimentally determined)
203
204
205 $DES
206 ;; ----- Compartment concentrations ----- ;;
207
208
209 Cven1 = A(1)/Vven                    ; venous blood (CMS)

```

```

210 Aven1 = A(1)
211 Cven2 = A(2)/Vven      ; venous blood (colistine)
212 Aven2 = A(2)
213 Aurl = A(3)            ; urine quantities (CMS)
214 Chrt1 = A(4)/Vhrt      ; heart (CMS)
215 Clun1 = A(5)/Vlun      ; lung (CMS)
216 Cgio1 = A(6)/Vgio      ; gut (CMS)
217 Ckidmix1 = A(7)/Vkidmix ; kidney vascular (CMS)
218 Chep1 = A(8)/Vhep      ; liver (CMS)
219 Cmus1 = A(9) /Vmus      ; muscle (CMS)
220
221 Chrt2 = A(10)/Vhrt      ; heart (colistin)
222 Clun2 = A(11)/Vlun      ; lung (colistin)
223 Cgio2 = A(12)/Vgio      ; gut (colistin)
224 Ckidmix2 = A(13)/Vkidmix ; kidney vascular (colistin)
225 Chep2 = A(14)/Vhep      ; liver (colistin)
226 Cmus2 = A(15) /Vmus      ; muscle (colistin)
227
228 Cart1 = A(16)/Vart      ; arterial blood (CMS)
229 Aart1 = A(16)
230 Cbra1 = A(17)/Vbra      ; brain (CMS)
231 Cskn1 = A(18)/Vskn      ; skin (CMS)
232 Cadi1 = A(19)/Vadi      ; adipose (CMS)
233 Avessie1 = A(20)
234 Cvessie1 = A(20)/Vvessie ; bladder (CMS)
235 Ctub1 = A(21)/Vtub      ; tubules kidney (CMS)
236 Cres1 = A(22)/Vres      ; rest of body (CMS)
237
238 Aart2 = A(23)
239 Cart2 = A(23)/Vart      ; arterial blood (colistin)
240 Cbra2 = A(24)/Vbra      ; brain (colistin)
241 Cskn2 = A(25)/Vskn      ; skin (colistin)
242 Cadi2 = A(26)/Vadi      ; adipose (colistin)
243 Aur2 = A(27)            ; urine quantities (colistin)
244 Atub2 = A(28)
245 Ctub2 = A(28)/Vtub      ; tubules kidney (Colistin)
246 Cres2 = A(29)/Vres      ; rest of body (colistin)
247 Cvessie2 = A(30)/Vvessie ; bladder (colistin)
248
249 Adep1= A(31)            ; IM depot compartment (CMS)
250 Adep2 = A(32)            ; IM depot compartment (colistin)
251
252 CkidEV1 = A(33)/VkidEV   ; kidney extra-vascular compartment (CMS)
253 Akidcell = A(34)
254 Ckidcell = A(34)/(Vkidcel) ; kidney cellular compartment (CMS)
255
256 CkidEV2 = A(35)/VkidEV   ; kidney extra-vascular compartment (colistin)
257 Akidcel2 = A(36)
258 Ckidcel2 = A(36)/(Vkidcel) ; kidney cellular compartment (colistin)
259 Akideep2 = A(37)         ; kidney binding compartment (colistin)
260
261
262
263 AdeepV2 = A(38)          ;; colistin vein deep compartment
264 AdeepA2 = A(39)          ; colistin artery deep compartment
265
266
267
268 ;; ----- Tissue clearances ----- ;;
269 ;;;;CMS hydrolysis ;;
270
271 CLart1 = KHYD * Vart      ; artery
272 CLven1 = KHYD * Vven      ; vein
273 CLlun1 = KHYD * Vlun      ; lung
274 CLbra1 = KHYD * Vbra      ; brain
275 CLhrt1 = KHYD * Vhrt      ; heart
276 CLmus1 = KHYD * Vmus      ; muscles
277 CLskn1 = KHYD * Vskn      ; skin
278 CLadi1 = KHYD * Vadi      ; adipose
279 CLhep1 = KHYD * Vhep      ; liver
280 CLgio1 = KHYD * Vgio      ; GIO
281 CLtub1 = KHYD * Vtub      ; tubules
282 CLkidmix1 = KHYD * Vkidmix ; vascular kidney

```

```

283 CLkidEV1 = KHYD * VkidEV      ; extra-vascular kidney
284 CLkidcel1 = KHYD * (Vkidcel)   ; cellular kidney
285 CLres1 = KHYD * Vres           ; Rest of body
286
287
288 ;;;;;;;;;;Colistin degradation clearance ;;;;;;;;;;
289
290
291 CLart2 = KNR * Vart            ; artery
292 CLven2 = KNR * Vven            ; vein
293 CLlun2 = KNR * Vlun            ; lung
294 CLbra2 = KNR * Vbra            ; brain
295 CLhrt2 = KNR * Vhrt            ; heart
296 CLskn2 = KNR * Vskn            ; skin
297 CLmus2 = KNR * Vmus            ; muscles
298 CLadi2 = KNR * Vadi            ; adipose
299 CLgio2 = KNR * Vgio            ; GIO
300 CLhep2 = KNR * Vhep            ; liver
301 CLtub2 = KNR * Vtub            ; tubules
302 CLkidmix2 = KNR * Vkidmix       ; vascular kidney
303 CLkidEV2 = KNR * VkidEV        ; extra-vascular kidney
304 CLkidcel2 = KNR * (Vkidcel)     ; cellular kidney
305 CLres2 = KNR * Vres             ; Rest of body
306
307
308
309 ;; ----- Abbreviations ----- ;;
310 PCMS=1631.97                    ; CMS molecular weight
311 PCOL=1166.8                     ; colistin molecular weight
312
313 RPM = PCOL/PCMS                  ; ratio of molecular weights
314
315
316 CLRcms = fu_cms * GFR            ; Clearance of glomerular filtration (CMS)
317 CLRcoli= fu_coli * GFR          ; Clearance of glomerular filtration (colistin)
318
319
320 VENinA = (Cbra1*Qbra/Kmix1) + (Cmus1*Qmus/Kmix1) + (Chrt1*Qhrt/Kmix1) +
321 (Cskn1*Qskn/Kmix1)
322 VENinB = (Cadil*Qadi/Kmix1) + (Chep1*QhepT/Kmix1) + (CkidEV1*(Qkid))
323 + (Cres1*Qres/Kmix1)
324 VENoutA = (Qven*Cven1) + (Cven1*CLven1)
325
326
327 HEPinA = (QhepArt*Cart1) + (Qgio*Cgio1/Kmix1)
328 HEPoutA = (QhepT*Chep1/Kmix1) + (Chep1*CLhep1)
329
330
331 VENinC = (Cbra2*Qbra/Kbra2) + Cmus2*Qmus/Kmus2 + (Chrt2*Qhrt/Khrt2) +
332 (Cskn2*Qskn/Kskn2)
333
334 VENinD = (Cadi2*Qadi/Kadi2) + (Chep2*QhepT/Khep2) + (CkidEV2*(Qkid))
335 + (Cres2*Qres/Kres2) + (Cven1*CLven1)*RPM
336
337 VENoutB = (Qlun*Cven2) + (Cven2*CLven2)
338
339
340 HEPinB = (Cart2*QhepArt) + (Qgio*Cgio2/Kgio2) + (Chep1*CLhep1)*RPM
341 HEPoutB = (QhepT*Chep2/Khep2) + CLhep2*Chep2
342
343
344
345
346
347
348
349
350 ;; ----- Differential equations ----- ;;
351
352
353
354 DADT(1) = VENinA + VENinB - VENoutA + ka1 * (Adep1) ; venous blood (CMS)
355 DADT(2) = VENinC + VENinD - VENoutB + ka2 * (Adep2) - kb2*Aven2 +
356 kb2_out*AdeepV2 ; venous blood (colistin)
357
358 DADT(3) = Cvessiel*Quri ; urine (CMS)
359
360 DADT(4) = Qhrt * (Cart1 - Chrt1/Kmix1) - Chrt1*CLhrt1 ; heart (CMS)
361 DADT(5) = Qlun * (Cven1 - Clun1/Kmix1) - Clun1*CLlun1 ; lung (CMS)

```

```

351 DADT(6) = Qgio * (Cart1 - Cgio1/Kmix1) - Cgio1*CLgio1 ; GIO (CMS)
352 DADT(7) = Qkid * (Cart1 - Ckidmix1) - Ckidmix1*CLkidmix1 ; kidney vascular
(CMS)
353 DADT(8) = HEPinA - HEPoutA ; liver (CMS)
354 DADT(9) = Qmus * (Cart1 - Cmus1/Kmix1) - Cmus1*CLmus1 ; muscle (CMS)
355
356 DADT(10) = Qhrt * (Cart2 - Chrt2/Khrt2) + Chrt1*(CLhrt1)*RPM - Chrt2*CLhrt2
; heart (colistin)
357 DADT(11) = Qlun * (Cven2 - Clun2/Klun2) + Clun1*(CLlun1)*RPM - Clun2*CLlun2
; lung (colistin)
358 DADT(12) = Qgio * (Cart2 - Cgio2/Kgio2) + Cgio1*(CLgio1)*RPM - Cgio2*CLgio2
; GIO (colistin)
359 DADT(13) = Qkid * (Cart2 - Ckidmix2) - Ckidmix2*CLkidmix2 + Ckidmix1*CLkidmix1*RPM
; kidney vascular (colistin)
360 DADT(14) = HEPinB - HEPoutB
; liver (colistin)
361 DADT(15) = Qmus * (Cart2 - Cmus2/Kmus2) + Cmus1*(CLmus1)*RPM - Cmus2*CLmus2
; muscle (colistin)
362
363 DADT(16) = (Qlun*Clun1/Kmix1) - (Cart1*CLart1) - (Qart*Cart1) ;
arterial blood (CMS)
364 DADT(17) = Qbra * (Cart1 - Cbra1/Kmix1) - Cbra1*CLbra1 ;
brain blood (CMS)
365 DADT(18) = Qskn * (Cart1 - Cskn1/Kmix1) - Cskn1*CLskn1 ;
skin (CMS)
366 DADT(19) = Qadi * (Cart1 - Cadi1/Kmix1) - Cadi1*CLadi1 ;
adipose (CMS)
367 DADT(20) = Ctub1*Qtub - Cvessie1*Quri ;
bladder (CMS)
368 DADT(21) = Ckidmix1 * CLRcms + CLsec1*Ckidcell - Ctub1* (Qtub) - Ctub1*CLtub1 ;
tubules (CMS)
369 DADT(22) = Qres * (Cart1 - Cres1/Kmix1) - Cres1*CLres1 ;
rest of body (CMS)
370
371
372
373 DADT(23) = Qlun*Clun2/Klun2 + Cart1*CLart1*RPM - Qart*Cart2 - Cart2*CLart2 -
kb2*Aart2 + kb2_out*AdeepA2 ; arterial blood (colistin)
; arterial blood colistin
374 DADT(24) = Qbra * (Cart2 - Cbra2/Kbra2) + Cbra1*(CLbra1)*RPM -
Cbra2*CLbra2 ; brain (colistin)
375 DADT(25) = Qskn * (Cart2 - Cskn2/Kskn2) + Cskn1*(CLskn1)*RPM -
Cskn2*CLskn2 ; skin (colistin)
376 DADT(26) = Qadi * (Cart2 - Cadi2/Kadi2) + Cadi1*(CLadi1)*RPM -
Cadi2*CLadi2 ; adipose (colistin)
377 DADT(27) =
Cvessie2*Quri*(1/RPM) ;
urine (colistin)
378 DADT(28) = Ckidmix2 * CLRcoli + Ctub1*CLtub1*RPM - Ctub2*(CLtub2+Qtub) - Ctub2
*CLreab2 ; tubules (colistin)
379 DADT(29) = Qres * (Cart2 - Cres2/Kres2) + Cres1*(CLres1)*RPM -
Cres2*CLres2 ; rest of body (colistin)
380
381 DADT(30) = (Ctub2*Qtub -
Cvessie2*Quri)*(1/RPM) ; bladder
colistin conversion into CMS
382
383 DADT(31) = - ka1 * Adepl - KHYD *
Adepl ; IM depot compartment (CMS)
384 DADT(32) = KHYD*Adepl*RPM - ka2 * Adep2 - KNR *
Adep2 ; IM depot compartment (colistin)
385
386 DADT(33) = (Qkid-CLRcms)*Ckidmix1 - CkidEV1*(CLkidEV1 + CLsec1) -
CkidEV1*Qkid ; kidney extra-vascular compartment (CMS)
387 DADT(34) = CkidEV1*CLsec1 -
Ckidcell*(CLkidcell+CLsec1) ; kidney cellular
compartment (CMS)
388
389
390 DADT(35) = (Qkid-CLRcoli)*Ckidmix2 - CkidEV2*(CLkidEV2) - CkidEV2*Qkid
+CkidEV1*CLkidEV1 *RPM ; kidney extra-vascular compartment (colistin)
391 DADT(36) = Ctub2 *CLreab2 - Ckidcel2*CLkidcel2 + Ckidcell*CLkidcell*RPM +
k_off2*Akideep2 - k_on2*Akidcel2 ; kidney cellular compartment (colistin)

```

```

392 DADT(37) = k_on2*Akidcel2 -
      k_off2*Akideep2 ; kidney
      binding compartment (colistin)
393
394
395 DADT(38) = kb2*(Aven2) - kb2_out*AdeepV2 ;
      colistin vein deep compartment
396 DADT(39) = kb2*(Aart2) - kb2_out*AdeepA2 ;
      colistin artery deep compartment
397
398 ; ----- Mass balance check ----- ;
399
400 Az = Cart2*CLart2 + (Cven2*CLven2) + Clun2*CLlun2 + Cbra2*CLbra2 + Chrt2*CLhrt2
      + Cmus2*CLmus2 + Cskn2*CLskn2 + Cadi2*CLadi2
401 Bz = Cgio2*CLgio2 + Cres2*CLres2 + CLhep2*Chep2 + KNR*Adep2 + Ckidmix2*CLkidmix2 +
      Ckidcel2*CLkidcel2 + CkidEV2*CLkidEV2 + Ctub2*CLtub2
402
403
404 DADT(40) = Az + Bz ; colistin elimination by degradation
405
406 CMS = A(1) + A(3) + A(4) + A(5) + A(6) + A(7) + A(8) + A(9) + A(16) + A(17) + A(18)
      + A(19) + A(20) + A(21) + A(22) + A(27) + A(30) + A(31) + A(33) + A(34)
407
408 COLI = A(2) + A(10) + A(11) + A(12) + A(13) + A(14) + A(15) + A(23) + A(24) + A(25)
      + A(26) + A(28) + A(29) + A(32) + A(35) + A(36) + A(37) + A(38) + A(39)
409
410 MB = CMS + (A(40) + COLI) * (1/RPM) ; mass balance
411
412
413
414 ;-----
415 $ERROR (ONLY OBSERVATIONS)
416 ;-----
417
418 CCven1 = A(1)/Vven ; venous blood (CMS)
419 CCven2 = A(2)/Vven ; venous blood (colistin)
420
421 AAur1 = A(3) ; urinary (CMS)
422 CChrt1 = A(4)/Vhrt ; heart (CMS)
423 CClun1 = A(5)/Vlun ; lung (CMS)
424 CCgio1 = A(6)/Vgio ; gut (CMS)
425 CCKidmix1 = A(7)/Vkidmix ; kidney vascular (CMS)
426 CCKid1 = (A(7) + A(33) + A(34) + A(21))/Vkid ; kidney (CMS)
427 CChep1 = A(8)/Vhep ; liver (CMS)
428 CCmus1 = A(9)/Vmus ; muscle (CMS)
429
430 CChrt2 = A(10)/Vhrt ; heart (colistin)
431 CClun2 = A(11)/Vlun ; lung (colistin)
432 CCgio2 = A(12)/Vgio ; gut (colistin)
433 CCKidmix2 = A(13)/Vkidmix ; kidney vascular (colistin)
434 CCKid2 = (A(13) + A(36) + A(37) + A(35) + A(28))/Vkid ; kidney (colistin)
435 CChep2 = A(14)/Vhep ; liver (colistin)
436 CCmus2 = A(15)/Vmus ; muscle (colistin)
437
438
439 CCart1 = A(16)/Vart ; arterial blood (CMS)
440 CCbra1 = A(17)/Vbra ; brain (CMS)
441 CCskn1 = A(18)/Vskn ; skin (CMS)
442 CCadi1 = A(19)/Vadi ; adipose (CMS)
443 CCvessie = A(20)/Vvessie ; bladder (CMS)
444 CCTub1 = A(21)/Vtub ; tubules (CMS)
445 CCres1 = A(22)/Vres ; rest of body (CMS)
446
447
448
449 CCart2 = A(23)/Vart ; arterial blood (colistin)
450 CCbra2 = A(24)/Vbra ; brain (colistin)
451 CCskn2 = A(25)/Vskn ; skin (colistin)
452 CCadi2 = A(26)/Vadi ; adipose (colistin)
453 AAur2 = A(27) ; urine (colistin)
454 CCTub2 = A(28)/Vtub ; tubules (colistin)
455 CCres2 = A(29)/Vres ; rest of body (colistin)
456

```

```

457 AAdep1 = A(31) ; ; IM depot compartment (CMS)
458 AAdep2 = A(32) ; ; IM depot compartment (colistin)
459
460
461 CCKidEV1 = A(33)/VkidEV ; ; kidney extra-vascular (CMS)
462 CCKidcel1 = A(34)/(Vkidcel) ; ; kidney cellular (CMS)
463
464
465 CCKidEV2 = A(35)/VkidEV ; ; kidney extra-vascular (colistin)
466 CCKidcel2 = A(36)/(Vkidcel) ; ; kidney cellular (colistin)
467 AAkideep2 = A(37) ; ; kidney binding (colistin)
468
469
470 AAurtot = A(3)+ A(27) ; SUM colistin and CMS in Urine
471
472
473 AAdeepV2 = A(38) ; ; colistin vein deep compartment
474 AAdeepA2 = A(39) ; ; colistin artery deep compartment
475
476
477
478 ; ;-----log transformation-----
479
480 LN_CCKid1 = LOG(CCKid1)
481 LN_CCKid2 = LOG(CCKid2)
482
483 LN_CCKidmix1 = LOG(CCKidmix1)
484 LN_CCKidmix2 = LOG(CCKidmix2)
485
486 LN_AAurtot = LOG (AAurtot)
487
488 LN_CCKidtot = LOG(CCKid1+CCKid2) ; SUM colistin and CMS in kidney
489 CCKidtot = (CCKid1+CCKid2)
490
491 ; ;-----
492
493 AA1 = A(1)
494 AA2 = A(2)
495 AA3 = A(3)
496 AA4 = A(4)
497 AA5 = A(5)
498 AA6 = A(6)
499 AA7 = A(7)
500 AA8 = A(8)
501 AA9 = A(9)
502 AA10 = A(10)
503 AA11 = A(11)
504 AA12 = A(12)
505 AA13 = A(13)
506 AA14 = A(14)
507 AA15 = A(15)
508 AA16 = A(16)
509 AA17 = A(17)
510 AA18 = A(18)
511 AA19 = A(19)
512 AA20 = A(20)
513 AA21 = A(21)
514 AA22 = A(22)
515 AA23 = A(23)
516 AA24 = A(24)
517 AA25 = A(25)
518 AA26 = A(26)
519 AA27 = A(27)
520 AA28 = A(28)
521 AA29 = A(29)
522 AA30 = A(30)
523 AA31 = A(31)
524 AA31 = A(31)
525 AA32 = A(32)
526 AA33 = A(33)
527 AA34 = A(34)
528 AA35 = A(35)
529 AA36 = A(36)

```



```

530 AA37 = A(37)
531 AA38 = A(38)
532 AA39 = A(39)
533 AA40 = A(40)
534
535
536 IF (CCven1.LE.0) CCven1=0.00001
537 IF (CCven2.LE.0) CCven2=0.00001
538 IF (AAur1.LE.0) AAur1=0.00001
539 IF (CCKid1.LE.0) CCKid1=0.00001
540 IF (CCKid2.LE.0) CCKid2=0.00001
541
542 IF (CMT.EQ.1.AND.LLOQ.EQ.0) THEN ; Plasma experimental data (CMS)
543 IPRED = LOG(CCven1)
544 IRES = DV-IPRED
545 Y = IPRED + EPS(1)
546 IWRES = IRES/EPS(1)
547 ENDIF
548
549
550 IF (CMT.EQ.2.AND.LLOQ.EQ.0) THEN ; Plasma experimental data (colistin)
551
552 IPRED = LOG(CCven2)
553 IRES = DV-IPRED
554 Y = IPRED + EPS(2)
555 IWRES = IRES/EPS(2)
556 ENDIF
557
558 IF (CMT.EQ.3) THEN ; Urine experimental data (CMS+Colistin)
559 IPRED = LOG(AAurtot)
560 IRES = DV-IPRED
561 Y = IPRED + EPS(5)
562 IWRES = IRES/EPS(5)
563 ENDIF
564
565 IF (CMT.EQ.7.AND.LLOQ.EQ.0) THEN ; Kidney experimental data (CMS+Colistin)
566 IPRED = LOG(0.8*(CCKid1+CCKid2)) ; only kidney cortex concentrations
567 equal to 80 % of total kidney
568 IRES = DV-IPRED
569 Y = IPRED + EPS(3)
570 IWRES = IRES/EPS(3)
571 ENDIF
572
573
574 IF (CMT.EQ.4.AND.LLOQ.EQ.0) THEN ; Heart tissue experimental data,
575 for Kp calculation (CMS)
576 IPRED = LOG(CChrt1)
577 IRES = DV-IPRED
578 Y = IPRED + EPS(4)
579 IWRES = IRES/EPS(4)
580 ENDIF
581
582 IF (CMT.EQ.5.AND.LLOQ.EQ.0) THEN ; Lung tissue experimental data, for
583 Kp calculation (CMS)
584 IPRED = LOG(CClun1)
585 IRES = DV-IPRED
586 Y = IPRED + EPS(4)
587 IWRES = IRES/EPS(4)
588 ENDIF
589
590 IF (CMT.EQ.6.AND.LLOQ.EQ.0) THEN ; GIO tissue experimental data, for
591 Kp calculation (CMS)
592 IPRED = LOG(CCgio1)
593 IRES = DV-IPRED
594 Y = IPRED + EPS(4)
595 IWRES = IRES/EPS(4)
596 ENDIF
597
598 IF (CMT.EQ.8.AND.LLOQ.EQ.0) THEN ; Liver tissue experimental data, for Kp
599 calculation (CMS)
600 IPRED = LOG(CChep1)

```

```

598 IRES = DV-IPRED
599 Y = IPRED + EPS(4)
600 IWRES = IRES/EPS(4)
601 ENDIF
602
603 IF (CMT.EQ.9.AND.LLOQ.EQ.0) THEN ; Muscles tissue experimental data, for
Kp calculation (CMS)
604 IPRED = LOG(CCmus1)
605 IRES = DV-IPRED
606 Y = IPRED + EPS(4)
607 IWRES = IRES/EPS(4)
608 ENDIF
609
610 IF (CMT.EQ.17.AND.LLOQ.EQ.0) THEN ; Brain tissue experimental data, for Kp
calculation (CMS)
611 IPRED = LOG(CCbra1)
612 IRES = DV-IPRED
613 Y = IPRED + EPS(4)
614 IWRES = IRES/EPS(4)
615 ENDIF
616
617 IF (CMT.EQ.18.AND.LLOQ.EQ.0) THEN ; Skin tissue experimental data, for Kp
calculation (CMS)
618 IPRED = LOG(CCskn1)
619 IRES = DV-IPRED
620 Y = IPRED + EPS(4)
621 IWRES = IRES/EPS(4)
622 ENDIF
623
624 IF (CMT.EQ.19.AND.LLOQ.EQ.0) THEN ; Adipose tissue experimental data, for
Kp calculation (CMS)
625 IPRED = LOG(CCadil1)
626 IRES = DV-IPRED
627 Y = IPRED + EPS(4)
628 IWRES = IRES/EPS(4)
629 ENDIF
630
631
632
633 ;;;;;;;;;;;;;; DATA BLOQ ;;;;;;;;;;;;;;
634
635 IF (CMT.EQ.1.AND.LLOQ.EQ.1) THEN
636 F_FLAG=1 ; what is fitted to Y is a probability
637 LOQ=LOG(0.15) ; LOQ of CMS in plasma
638 IPRED = LOG(CCven1)
639 IRES = DV-IPRED
640 W = SIGMA(1,1)
641 DUM=(LOQ-IPRED)/(W+0.0001)
642 CUMD=PHI(DUM) ; PHI = cumulative density function
643 Y = CUMD
644 ENDIF
645
646 IF (CMT.EQ.2.AND.LLOQ.EQ.1) THEN
647 F_FLAG=1 ; what is fitted to Y is a probability
648 LOQ=LOG(0.02) ; LOQ of colistin in plasma
649 IPRED = LOG(CCven2)
650 IRES = DV-IPRED
651 W = SIGMA(2,2)
652 DUM=(LOQ-IPRED)/(W+0.0001)
653 CUMD=PHI(DUM) ; PHI = cumulative density function
654 Y = CUMD
655 ENDIF
656
657 IF (CMT.EQ.7.AND.LLOQ.EQ.1) THEN
658 F_FLAG=1 ; what is fitted to Y is a probability
659 LOQ=LOG(1) ; LOQ of kidney for CMS and colistin
660 IPRED = LOG(0.8*(CCKid1+CCKid2))
661 IRES = DV-IPRED
662 W = SIGMA(3,3)
663 DUM=(LOQ-IPRED)/(W+0.0001)
664 CUMD=PHI(DUM) ; PHI = cumulative density function
665 Y = CUMD
666 ENDIF

```

```

667
668
669
670 IF (CMT.EQ.4.AND.LLOQ.EQ.1) THEN
671 F_FLAG=1 ; what is fitted to Y is a probability
672 LOQ=LOG(1) ; LOQ of tissue for CMS
673 IPRED = LOG(CChrt1)
674 IRES = DV-IPRED
675 W = SIGMA(4,4)
676 DUM=(LOQ-IPRED)/(W+0.0001)
677 CUMD=PHI(DUM) ; PHI = cumulative density function
678 Y = CUMD
679 ENDIF
680
681 IF (CMT.EQ.5.AND.LLOQ.EQ.1) THEN
682 F_FLAG=1 ; what is fitted to Y is a probability
683 LOQ=LOG(1) ; LOQ of tissue for CMS
684 IPRED = LOG(CCln1)
685 IRES = DV-IPRED
686 W = SIGMA(4,4)
687 DUM=(LOQ-IPRED)/(W+0.0001)
688 CUMD=PHI(DUM) ; PHI = cumulative density function
689 Y = CUMD
690 ENDIF
691
692 IF (CMT.EQ.6.AND.LLOQ.EQ.1) THEN
693 F_FLAG=1 ; what is fitted to Y is a probability
694 LOQ=LOG(1) ; LOQ of tissue for CMS
695 IPRED = LOG(CCgio1)
696 IRES = DV-IPRED
697 W = SIGMA(4,4)
698 DUM=(LOQ-IPRED)/(W+0.0001)
699 CUMD=PHI(DUM) ; PHI = cumulative density function
700 Y = CUMD
701 ENDIF
702
703 IF (CMT.EQ.8.AND.LLOQ.EQ.1) THEN
704 F_FLAG=1 ; what is fitted to Y is a probability
705 LOQ=LOG(1) ; LOQ of tissue for CMS
706 IPRED = LOG(CCchep1)
707 IRES = DV-IPRED
708 W = SIGMA(4,4)
709 DUM=(LOQ-IPRED)/(W+0.0001)
710 CUMD=PHI(DUM) ; PHI = cumulative density function
711 Y = CUMD
712 ENDIF
713
714 IF (CMT.EQ.9.AND.LLOQ.EQ.1) THEN
715 F_FLAG=1 ; what is fitted to Y is a probability
716 LOQ=LOG(1) ; LOQ of tissue for CMS
717 IPRED = LOG(CCmus1)
718 IRES = DV-IPRED
719 W = SIGMA(4,4)
720 DUM=(LOQ-IPRED)/(W+0.0001)
721 CUMD=PHI(DUM) ; PHI = cumulative density function
722 Y = CUMD
723 ENDIF
724
725 IF (CMT.EQ.17.AND.LLOQ.EQ.1) THEN
726 F_FLAG=1 ; what is fitted to Y is a probability
727 LOQ=LOG(1) ; LOQ of tissue for CMS
728 IPRED = LOG(CCbra1)
729 IRES = DV-IPRED
730 W = SIGMA(4,4)
731 DUM=(LOQ-IPRED)/(W+0.0001)
732 CUMD=PHI(DUM) ; PHI = cumulative density function
733 Y = CUMD
734 ENDIF
735
736 IF (CMT.EQ.18.AND.LLOQ.EQ.1) THEN
737 F_FLAG=1 ; what is fitted to Y is a probability
738 LOQ=LOG(1) ; LOQ of tissue for CMS
739 IPRED = LOG(CCsKn1)

```

```

740 IRES = DV-IPRED
741 W = SIGMA(4,4)
742 DUM=(LOQ-IPRED)/(W+0.0001)
743 CUMD=PHI(DUM) ; PHI = cumulative density function
744 Y = CUMD
745 ENDIF
746
747 IF (CMT.EQ.19.AND.LLOQ.EQ.1) THEN
748 F_FLAG=1 ; what is fitted to Y is a probability
749 LOQ=LOG(1) ; LOQ of tissue for CMS
750 IPRED = LOG(CCadil)
751 IRES = DV-IPRED
752 W = SIGMA(4,4)
753 DUM=(LOQ-IPRED)/(W+0.0001)
754 CUMD=PHI(DUM) ; PHI = cumulative density function
755 Y = CUMD
756 ENDIF
757
758 ;;-----
759
760 $THETA
761 (0.01,0.283,10) ; hydrolysis constant of CMS into colistin
762 (0.01,0.416,10) ; degradation constant of colistin
763 0.37 FIX ; Unbound fraction CMS ; NOT ESTIMATED
764 0.4 FIX ; Unbound fraction colistin ; NOT ESTIMATED
765 0.4 FIX ; Kp of rest of body (colistin) ; NOT ESTIMATED
766 (average of Kps of colistin)
767 (0.1,1.96,15) ; Absorption constant of CMS for intra-muscular route
768 (0.1,3.35,10) ; Absorption constant of colistin for intra-muscular route
769 0 FIX ; NOT USED
770 (0.01,0.216,2) ; Kp of CMS compartments (common for all compartments)
771 (0,0.24,15) ; "Binding" constant of colistin in vascular compartments
772 (0,0.12,5) ; "Unbinding" constant of colistin in vascular
773 compartments
774 (0.01,0.0915,5) ; "Binding" constant of colistin in kidney intracellular
775 compartments
776 (0,0.014,5) ; "UnBinding" constant of colistin in kidney
777 intracellular compartments
778 106 FIX ; Reabsorption of colistin tubular lumen into
779 intracellular compartment ; NOT ESTIMATED
780 (0.01,7.22,50) ; Tubular CMS secretion from kidney vascular space to
781 tubular lumen
782
783 $OMEGA 0 FIX ; 1 ~IIV_Khyd
784 $OMEGA 0.0926 ; 2 ~IIV_KNR
785 $OMEGA 0 FIX ; 3 ~IIV_fu cms
786 $OMEGA 0 FIX ; 4~IIV_fu coli
787 $OMEGA 0 FIX ; 5 ~IIV_Kres2
788 $OMEGA 0 FIX ; 6 ~IIV_ka1
789 $OMEGA 0 FIX ; 7 ~IIV_ka2
790 $OMEGA 0 FIX ; 8 ~IIV_KNRcel
791 $OMEGA 0 FIX ; 19 ~IIV_Kmix1
792 $OMEGA 0 FIX ; 10 ~IIV_kb2
793 $OMEGA 0 FIX ; 11 ~IIV_kbout2
794 $OMEGA 0 FIX ; 14 ~IIV_k_on2
795 $OMEGA 0 FIX ; 16 ~IIV_koff2
796 $OMEGA 0 FIX ; 17 ~IIV_CLreabs2
797 $OMEGA 0.1 ; 18 ~IIV_CLsec1
798 $OMEGA 0 FIX ; 21 ~IIV_Klun2
799 $OMEGA 0 FIX ; 22 ~IIV_Kbra2
800 $OMEGA 0 FIX ; 23 ~IIV_Khrt2
801 $OMEGA 0 FIX ; 24 ~IIV_Kskn2
802 $OMEGA 0 FIX ; 25 ~IIV_Kmus2
803 $OMEGA 0 FIX ; 26 ~IIV_Kadi2
804 $OMEGA 0 FIX ; 27 ~IIV_Kgio2
805 $OMEGA 0 FIX ; 28 ~IIV_Khep2
806
807 $$SIGMA BLOCK(2)
808 0.209 ; residual variability CMS plasma
809 0.1 0.164 ; residual variability Coli plasma
810 $SIGMA 0.296 ; residual variability Kidney
811 $SIGMA 0.0799 ; residual variability CMS Kp
812 $SIGMA 0.257 ; residual variability CMS urine

```

```

807
808 $ESTIMATION PRINT=5 MAX=9999 NSIG=2 SIGL=6 METHOD=1 INTERACTION
809 LAPLACIAN POSTHOC NOABORT
810
811 $COVARIANCE UNCONDITIONAL MATRIX=R PRINT=E
812
813 $TABLE ID TIME CMT DV PRED IPRED IRES WRES NOPRINT ONEHEADER
814 FILE=sdtabZ81
815
816 $TABLE ID TIME CMT CCart1 CCven1 CClun1 CChrt1 CCgio1 CCKid1
817 CCKidmix1 CChep1 CCmus1 CCskn1 CCbra1 CCadi1 CCres1 CCTub1
818 CCart2 CCven2 CClun2 CChrt2 CCgio2 CCKid2 CCKidmix2 CChep2
819 CCmus2 CCskn2 CCbra2 CCadi2 CCres2 CCTub2 CCKidEV1
820 CCKidcell1 CCKidEV2 CCKidcel2 AAkideep2 MDV AAur1 AAur2
821 Adep1 Adep2 AAddeepV2 AAddeepA2 AAurtot LN_AAurtot CCKidtot
822 LN_CCKidtot DV MB IPRED LN_CCKid1 LN_CCKid2 LN_CCKidmix1
823 LN_CCKidmix2 NOPRINT ONEHEADER FILE=mytabZ82
824
825 $TABLE ID TIME fu_cms KHYD KNR ka1 ETA1 ETA2 ETA3 ETA4 ETA5 L2
826 NOPRINT ONEHEADER NOAPPEND FILE=patabZ81
827
828 $TABLE ID TIME AA1 AA2 AA3 AA4 AA5 AA6 AA7 AA8 AA9 AA10 AA11 AA12
829 AA13 AA14 AA15 AA16 AA17 AA18 AA19 AA20 AA21 AA22 AA23
830 AA24 AA25 AA26 AA27 AA28 AA29 AA30 AA31 AA32 AA33 AA34
831 AA35 AA36 AA37 AA38 AA39 AA40 MB NOPRINT ONEHEADER
832 FILE=mytabZ81_2
833
834 $TABLE ID TIME CLart1 CLart2 CLven1 CLven2 CLlun1 CLlun2 CLbra1
835 CLbra2 CLhrt1 CLhrt2 CLskn1 CLskn2 CLmus1 CLmus2 CLadi1
836 CLadi2 CLgio1 CLgio2 CLhep1 CLhep2 CLtub1 CLtub2 NOPRINT
837 ONEHEADER FILE=mytabZ81_1
838

```